1 A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind,

2 Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular

3 or Intranasal Administration to Evaluate the Safety and Immunogenicity of the

4 Recombinant Vaccine Against COVID-19 (AVX/COVID-12 "Patria") Based on an

5 Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects

6 with Evidence of Previous Immunity to SARS-CoV-2.

Constantino López-Macías<sup>1\*</sup>, Martha Torres<sup>2</sup>, Brenda Armenta-Copca<sup>3</sup>, Niels 7 Wacher<sup>4</sup>, Laura Castro-Castrezana<sup>5</sup>, Andrea Alicia Colli-Domínguez<sup>6</sup>, Tania Rivera-8 Hernández<sup>1,7</sup>, Alejandro Torres-Flores<sup>1,8</sup>, Luis Ramírez-Martínez<sup>9</sup>, Georgina Paz-De 9 la Rosa<sup>9</sup>, Oscar Rojas-Martínez<sup>9</sup>, Alejandro Suárez-Martínez<sup>9</sup>, Gustavo Peralta-10 Sánchez<sup>9</sup>, Claudia Carranza<sup>2</sup>, Esmeralda Juárez<sup>10</sup>, Horacio Zamudio-Meza<sup>2</sup>, Laura 11 E. Carreto-Binaghi<sup>2</sup>, Mercedes Viettri<sup>2</sup>, Damaris Romero-Rodríguez<sup>11</sup>, Andrea 12 Palencia<sup>2</sup>, Edgar Reyna-Rosas<sup>2</sup>, José E. Márguez-García<sup>2</sup>, David Sarfati-Mizrahi<sup>9</sup>, 13 Weina Sun<sup>12</sup>, Héctor Elías Chagoya-Cortés<sup>13</sup>, Felipa Castro-Peralta<sup>9</sup>, Peter 14 Palese<sup>12</sup>, Florian Krammer<sup>12,14,15</sup>, Adolfo García-Sastre<sup>12,15,16,17,18,19</sup> and Bernardo 15 Lozano-Dubernard<sup>9\*</sup> 16

<sup>1</sup>Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de 17 Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro 18 Social (IMSS), Ciudad de México (CDMX), México.<sup>2</sup>Laboratorio de Inmunobiología 19 de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) 20 "Ismael Cosío Villegas", CDMX, México. <sup>3</sup>iLS Clinical Research, S.C., CDMX, 21 México. <sup>4</sup>Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital 22 de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, CDMX, México. 23 <sup>5</sup>CAIMED Investigación en Salud, S. A. de C. V., CDMX, México. <sup>6</sup>Oaxaca Site 24 Management Organization (OSMO) S.C., Oaxaca, México. <sup>7</sup>Investigadores por 25 México, Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), 26 CDMX, México. <sup>8</sup>Posgrado en Inmunología, Escuela Nacional de Ciencias 27 Biológicas, Instituto Politécnico Nacional, CDMX, México. <sup>9</sup>Laboratorio Avi-Mex S.A. 28 de C.V., CDMX, México. <sup>10</sup>Departamento de Investigación en Microbiología INER, 29 "Ismael Cosío Villegas", CDMX, México.<sup>11</sup>Unidad de Citometría INER, "Ismael 30 Cosío Villegas", CDMX, México. <sup>12</sup>Department of Microbiology, Icahn School of 31 Medicine at Mount Sinai, New York, NY, USA. <sup>13</sup>Consultora Mextrategy, S.A.S. de 32 C.V., CDMX, México. <sup>14</sup>Center for Vaccine Research and Pandemic Preparedness 33 (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. 34 <sup>15</sup>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of 35 Medicine at Mount Sinai, New York, NY, USA. <sup>16</sup>Department of Medicine, Division of 36 Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 37 <sup>17</sup>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at 38 Mount Sinai, New York, NY, USA. <sup>18</sup>The Tisch Cancer Institute, Icahn School of 39 Medicine at Mount Sinai, New York, NY, USA. <sup>19</sup>The Icahn Genomics Institute, Icahn 40 School of Medicine at Mount Sinai, New York, NY, USA. 41

42

43 \*Correspondence: lozano@avimex.com.mx (B. Lozano-Dubernard),
44 constantino.lopez@imss.gob.mx (C. López-Macías)

#### 45 Abstract

Background: The global inequity in coronavirus disease 2019 (COVID-19) vaccine
 distribution, primarily affecting low- and middle-income countries (LMICs), highlights
 the urgent need for innovative and cost-effective vaccine technologies to address
 availability disparities. This is crucial for achieving and sustaining widespread
 immunity and protecting vulnerable populations during future booster campaigns.

51 **Methods:** To address this need, we conducted a phase II clinical trial evaluating the

52 safety and immunogenicity of the AVX/COVID-12 "Patria" vaccine as a booster dose. 53 The vaccine was administered through both intramuscular (IM) and intranasal (IN) 54 routes to participants who had previously received severe acute respiratory 55 syndrome coronavirus 2 (SARS-CoV-2) vaccines based on adenoviral technology, 56 inactivated virus, or mRNA technology. The inclusion criterion involved individuals 57 with initial anti-spike IgG titers below 1,200 U/mL, allowing observation of the booster 58 effect induced by vaccination.

**Results:** Immunization with AVX/COVID-12 resulted in a significant (>2.5 times) increase in neutralizing antibodies against the original Wuhan strain and variants of concern (VOCs) such as Alpha, Beta, Delta, and Omicron (BA.2 and BA.5). This immune response was accompanied by cellular interferon-gamma (IFN- $\gamma$ ) production, indicating a robust and multifaceted reaction.

64 **Conclusions:** The administration of AVX/COVID-12 as a booster dose, whether 65 through IM or IN routes, was safe and well-tolerated. The vaccine extended immune 66 responses not only against the original Wuhan-1 strain but also against various 67 VOCs. Its ability to enhance preexisting immune responses suggests a potential 68 contribution to expanding and sustaining herd immunity within the population.

69

Keywords: COVID-19 vaccine booster, phase II clinical trial, Newcastle disease
 virus LaSota, SARS-CoV-2.

### 72 Introduction

Since 2020, SARS-CoV-2 and its variants have led to widespread infections and 73 millions of deaths worldwide (1). The unequal distribution of vaccines globally, 74 75 particularly impacting low- and middle-income countries (LMICs), underscores the necessity for developing new vaccine platforms to address distribution disparities 76 (2). Ensuring a high vaccination rate globally is crucial for achieving widespread 77 78 immunity. There is a strong possibility that administering periodic booster doses in 79 the future will be necessary to prevent subsequent waves of COVID-19. 80 Consequently, the global vaccine supply will continue to be a problem that needs to 81 be addressed.

Population protection against COVID-19 is achieved by immunity, which has been 82 83 extensively developed through a combination of infection and vaccination, including the use of vaccines that employ the spike protein from the original Wuhan-1 variant 84 of SARS-CoV-2 as an antigen. This protection is referred to as "hybrid immunity." 85 Various scientific articles have demonstrated that hybrid immunity is highly effective 86 in primarily preventing hospitalization and death caused by variants of concern, 87 including Omicron and its predominant subvariants, even though protection against 88 infection may have diminished (3.4). In other words, first-generation vaccines remain 89 valuable for strengthening and expanding acquired SARS-CoV-2 immunity, leading 90 the World Health Organization (WHO) to continue recommending their use when 91 vaccines targeting more recent variants are unavailable (5). 92

Supporting this point, it is noteworthy that hospitalization and mortality have 93 94 significantly decreased since the introduction of vaccination with first-generation vaccines. Some studies report a 25% reduction in the risk of hospitalization and a 95 96% reduction in mortality for each additional dose administered (6). In Mexico, the 96 97 mortality rate before vaccination was 1.04 per 1,000 inhabitants; after the implementation of vaccination and the development of hybrid immunity, a mortality 98 rate of 0.01 per 1,000 inhabitants has been achieved in the sixth wave, despite being 99 caused by different VOCs, including Omicron (7). 100

Unfortunately, the mutation rate of SARS-CoV-2 has been until now faster than our 101 capacity to generate updated vaccines. Nevertheless, it is desirable to develop 102 vaccines as close as possible to the circulating strains, aiming to protect not only 103 against hospitalization and death but also against symptomatic disease. 104 105 Furthermore, there is a need for the development of vaccines that prevent transmission. One possibility is the creation of vaccines that induce mucosal 106 immunity to avert the initial viral infection at the site of entrance, such as intranasally 107 administered vaccines. 108

The AVX/COVID-12 vaccine candidate "Patria" utilizes a vector based on the 109 Newcastle disease virus LaSota (NDV-LaSota), expressing a stabilized prefusion 110 conformation version of the spike (S) protein of the SARS-CoV-2, known as HexaPro 111 S (8,9). This vector presents distinct advantages, including a standardized 112 production process in embryonated chicken eggs, a method commonly used in 113 influenza vaccine manufacturing. This approach allows for efficient dose generation 114 and provides the added benefit of intranasal administration, further enhancing its 115 usability. The IN administration feature is particularly advantageous, offering an 116 alternative and potentially more accessible method of delivery compared to 117 traditional IM routes. This characteristic is desirable to expand vaccination coverage. 118 119 especially in areas with low immunization rates or incomplete vaccination schedules.

The NDV-LaSota vector expressing HexaPro S elicited a strong immune response with IgA, IgG2a antibodies, and IFN-γ-producing T cells when used in mice and

hamsters, providing complete protection against SARS-CoV-2 challenge. Trials in pigs assessed AVX/COVID-12 safety and immunogenicity via IM and IN administration, revealing no inflammation, fibrosis, or abscesses at the application site. The study demonstrated robust serum-neutralizing antibodies, cross-reactivity to spike protein epitopes in VOCs, and overall safety without signs of viral infection (10,11).

In a phase I clinical trial (NCT04871737) that included 91 volunteers, AVX/COVID-12's safety and immunogenicity were assessed with various prime-boost regimens administered IM and IN. Three 50% embryo infective doses (EID<sub>50%</sub>) (Low: 10<sup>7.0</sup> EID<sub>50%</sub>, Middle: 10<sup>7.5</sup> EID<sub>50%</sub> or High: 10<sup>8.0</sup> EID<sub>50%</sub>) were well-tolerated, with minimal reactogenicity. No serious adverse events were associated with any route or dose, confirming the vaccine's safety and immunogenic profile (12). The study laid the foundation for subsequent clinical development.

In this study, we assessed the safety and immunogenicity of the AVX/COVID-12
vaccine in a phase II clinical trial. Administered as a booster dose (both IM and IN),
AVX/COVID-12 was given to participants who had previously received SARS-CoV2 vaccines based on adenoviral technology, inactivated virus, or mRNA technology,
primarily with initial anti-S IgG titers below 1,200 U/mL. These titers were considered
low enough to observe the booster effect induced by the IM and IN administration of
AVX/COVID-12.

### 142 Material and methods

#### 143 Study design

A phase II study (ClinicalTrials.gov #NCT05205746) was conducted to assess the safety phase under single-blind conditions, followed by randomized, double-blind, placebo-controlled, single-dose administration via IM or IN routes, in subjects with evidence of prior immunity to SARS-CoV-2. This was followed by an assessment phase to evaluate the booster response, involving an IM dose of the COVID-19 vaccine (recombinant AZ/ChAdOx-1-S) in subjects originally randomized to the placebo arm.

The protocol was formulated by iLS Clinical Research, S.C. in collaboration with the 151 Mexican Institute for Social Security (IMSS) and Laboratorio Avi-Mex, S.A. de C.V. 152 (Avimex®), which was the sponsor. Approval for the study was granted by the 153 154 Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in Mexico, assigned the number RNEC2021-AVXSARSCoV2VAC002. Ethics approval 155 156 was obtained from the institutional ethics committee at each research site 157 participating in the study. The research was conducted in complete compliance with 158 Mexican regulations and by the principles outlined in the Declaration of Helsinki and

Good Clinical Practice. Immunological assay samples were processed at the National Institute for Respiratory Diseases (INER) in Mexico City.

#### 161 Study groups

The study groups included adults aged 18 years or older of both genders who signed 162 informed consent and had not experienced respiratory issues in the 21 days 163 164 preceding the administration of the single dose. Participants committed to 165 maintaining appropriate preventive measures to avoid SARS-CoV-2 infection 166 throughout their study participation, particularly during the initial 14 days following the baseline visit. Additionally, eligibility criteria involved having detectable anti-spike 167 168 IgG titers in serum during the screening visit, with titers levels less than 1,200 U/mL 169 measured in a chemiluminescence test. Furthermore, participants were required to provide evidence of vaccination, with a minimum of 4 months having passed since 170 the last vaccination. Due to the nature of the study, recruited subjects were enrolled 171 in one of three subgroups based on the vaccine technology used during the primary 172 immunization against SARS-CoV-2: subjects with a history of prior immunization with 173 vaccines based on adenoviral technology, inactivated virus, or mRNA technology. 174

The exclusion criteria encompassed hypersensitivity or allergy to any component of 175 176 the vaccine, a history of severe anaphylactic reactions, a history of seizures, 177 uncontrolled chronic diseases, chronic conditions requiring treatment with immunosuppressive agents or immune response modulators (e.g., systemic 178 corticosteroids, cyclosporine, rituximab, among others), the development of 179 oncological diseases, active participation in or involvement within the last three 180 months in any other clinical or experimental intervention study, use of any drug or 181 herbal supplement in the 30 days preceding the screening evaluation, or alternative 182 medicine (e.g., chlorine dioxide, etc.) aimed at treating or preventing complications 183 or SARS-CoV-2 infection, or any other condition, fever at the time of the screening 184 visit, and having received any vaccine (experimental or approved) in the 60 days 185 186 prior to the screening visit, except for the influenza vaccine. Exclusion criteria also included having received a blood or blood component transfusion, or being a plasma 187 donor within the 4 months prior to the screening visit, undergoing dialysis or 188 hemodialysis procedures in the last year before the screening visit, working on 189 poultry or gamecock farms, and having a history of substance abuse problems that, 190 in the investigator's judgment, could interfere with the subject's ability to comply 191 adequately with the protocol guidelines. 192

The randomization of volunteers was conducted using a computer-based random assignment system, ensuring blinding throughout the study. Upon signing the informed consent form, each participant received a patient number, encoding all their information in a pseudo-anonymized manner during data collection and becoming fully anonymized during the analysis.

#### 198 The stratification for subject randomization was generated as follows:

Safety phase: Involved single-blinded assignment (blinded to the research subject) to the arm receiving the AVX/COVID-12 vaccine for the first three subjects of each specific vaccine recruited in each branch, IM and IN. For this purpose, eight blocks of six vaccines were generated, and to each block, three subjects with the AVX/COVID-12 vaccine and three subjects with placebo were randomly assigned.

204 Double-blind, placebo-controlled randomized phase: subjects with the 205 corresponding vaccination history were randomized to receive a placebo or the AVX/COVID-12 vaccine in either of the two administration modalities (IM or IN). 206 Starting from block 9, blocks of 4 were generated, and each block was randomly 207 208 assigned 1 subject with IM AVX/COVID-12 vaccine, 1 subject with IN AVX/COVID-12 vaccine, 1 subject with IM placebo, and 1 subject with IN placebo. 209

After 14 days, following the administration of the AVX/COVID-12 vaccine or placebo, the blinding was revealed for subjects who received a placebo. These subjects

received an additional dose of the COVID-19 vaccine (AZ/ChAdOx-1-S) IM.

#### 213 AVX/COVID-12 vaccine preparation

The AVX/COVID-12 vaccine was manufactured in a purpose-built good 214 manufacturing practice (GMP) facility. The recombinant virus was cultivated in 10-215 day-old specific-pathogen-free (SPF) chicken embryos through inoculation via the 216 allantoic cavity with 10<sup>3.3</sup> EID<sub>50</sub>/0.1 mL of the production seed. The embryos were 217 incubated for a period of 72 hours (h) at an average temperature of 37 °C and a 218 relative humidity range of 60% to 70%. After this period, the embryos were 219 refrigerated for at least 12 h to sacrifice them. Harvesting of the allantoic fluid (AF) 220 was conducted under aseptic conditions using a vacuum. The AF was clarified 221 222 through filters with a pore size of 0.8 to 8.0 µm, concentrated by a factor of 10X in 223 300-kDa cassettes, and subjected to diafiltration in 20 volumes of phosphatebuffered saline (PBS). The AF was stored frozen at -70 °C. The AF yielded a titer of 224 225 10<sup>8.67</sup> EID<sub>50</sub>/mL, from which the frozen active vaccines were prepared. The 226 corresponding volumes of purified AF were aseptically mixed with the stabilizer trehalose, monobasic potassium phosphate, dibasic sodium phosphate and 227 228 monosodium glutamate and homogeneously mixed for 5 minutes using a Teflon bar and a magnetic stirrer. Finally, they were packed in high-density polyethylene 229 bottles. The vaccines were stored at -80 °C. 230

#### 231 Safety

232 Safety was assessed by comparing adverse events (AEs) between placebo and 233 AVX/COVID-12 vaccine groups, considering their severity and relationship to the 234 intervention. While all participants completed the same visits, those assigned to 235 specific groups underwent additional sample collections during visits corresponding

to days 0, 14, 42, 90, 180 and 365 of the study. The primary endpoints in the phase
II aspects of this trial included solicited local and systemic AEs. The classification of
potential AEs and their association with vaccine exposure followed a two-period
analysis. The first period included the initial seven days following vaccination, during
which AEs were deemed related to the vaccine components. Conversely, reactions
occurring after seven days, typically in response to the development of an immune
response, constituted the second period of analysis (13).

#### 243 Sample collection

244 Venous blood samples were obtained from participants during scheduled site visits 245 for serology tests and cellular response assessments. Using standard phlebotomy procedures, the samples were collected into two sodium heparin tubes and one 246 separator tube (SST BD vacutainer tubes, Franklin Lakes, NJ, USA). Following 247 collection, the samples were transported at room temperature to the INER for 248 immediate processing. All blood samples and products were handled in a BSL-2 249 laboratory, using appropriate personal protective equipment and safety precautions, 250 adhering to processing protocols approved by the Institutional Biosafety Committee. 251 252 Peripheral blood samples from each volunteer were centrifuged at 2,260 x g at roomtemperature for 10 minutes and transported to a biological safety cabinet. Then, for 253 each sample, the serum was recovered, divided into six aliquots of 200 µL, stored in 254 pre-labeled 1.5 mL cryovials according to the established procedure, and frozen at -255 20 °C until use. One aliquot of serum was thawed for each antibody determination, 256 and the remaining portion of each thawed aliquot was discarded as infectious 257 biological material (IBM). 258

### 259 **Peripheral blood mononuclear cell (PBMC) isolation**

260 PBMCs were isolated from venous blood collected in sodium heparin tubes (BD vacutainer tubes, Franklin Lakes, NJ, USA). Within four hours of collection, PBMC 261 isolation was conducted by density-gradient sedimentation of whole blood diluted at 262 a 1:2 ratio in Roswell Park Memorial Institute medium (RPMI) 1640 (Lonza, Basel, 263 Switzerland) at room-temperature. The diluted blood was layered over an 264 appropriate volume of Lymphoprep (Axis-Shield, Dundee, UK) at room-temperature. 265 Then, the PBMC were then recovered, cryopreserved in a medium consisting of 10% 266 267 dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, MO, USA) and 90% heatinactivated fetal bovine serum (FBS; GIBCO, California, USA), and stored at -80 °C 268 until use. For T-cell assays, the thawing process involved warming frozen cryovials 269 270 at 37 °C in a water bath, and cells were resuspended in 5 mL of CTS OpTmizer (GIBCO, California, USA). After a wash with OpTmizer, cells were counted using a 271 Neubauer chamber, and the viability was assessed by trypan blue; cells were 272 resuspended in OpTmizer medium to a density of 4 x 10<sup>6</sup> cells/mL. 273

The subunit 1 of the spike protein of SARS-CoV-2 (RayBiotech, Peachtree Corners, Georgia, USA) was selected as the primary antigen due to its display of the most immunogenic epitopes of the spike protein. Additionally, it contains the receptor binding domain (RBD) fragment of the virus, which mediates binding to the host receptor angiotensin-converting enzyme 2 (ACE2) in lung cells.

# 279 SARS-CoV-2 detection

Sample processing was conducted through nucleic acid extraction, followed by onestep real-time RT-PCR amplification and detection for SARS-CoV-2. A Roche
Magnapure instrument (Roche Diagnostics, Basel, Switzerland) was used for viral
RNA extraction, and the following ModularDx kits (TIB Molbiol, Berlin, Germany)
were employed:

- 53-0775-96 Sarbeco N-gene detects SARS and SARS-CoV-2
- 53-0776-96 Sarbeco E-gene detects SARS and SARS-CoV-2
- 53-0777-96 SARS-CoV-2 RdRP detects SARS-CoV-2

### 288 **Determination of IgG anti-SARS-CoV-2 binding antibodies**

289 For the determination of total anti-SARS-CoV-2 serum antibodies, a semi-290 quantitative enzyme-linked immunosorbent assay (ELISA) was employed to detect 291 IgG antibodies to the spike protein subunit 1 domain (ELISA anti-SARS-CoV-2 (IgG); Catalog # 2606-9601 G; EUROIMMUN, Lübeck, Germany). Samples were 292 processed according to the manufacturer's instructions and analyzed on the 293 EUROIMMUN Analyzer I (EUROIMMUN, Lübeck, Germany). Results are reported 294 semi-quantitatively in ELISA ratio, representing a measure of the relative antibody 295 concentration in participants' serum. For the calculation of the relative concentration, 296 the ratio of the extinction value of the control or sample to the extinction value of the 297 298 calibrator was determined using the following formula: relative concentration (ratio) = (extinction of control or volunteer sample) / (extinction of calibrator). 299

- Interpretation of results, in terms of positivity, was conducted according to themanufacturer's instructions:
- Ratio <0.80: Negative
- Ratio >0.8 to <1.1: Uncertain
- Ratio >1.1: Positive

To estimate the geometric mean titers (GMT) of the IgG anti-spike subunit 1 antibodies in participants' serum, serial dilutions (1:100, 1:300, 1:900, 1:2700, 1:5400) were performed for all serum samples with ratio values equal to or greater than 1.1 at the 1:100 dilution. For sera with ratio values < 0.8 at the 1:100 dilution, a titer of 1:20 was assigned for simplified analysis.

#### 310 **Pseudovirus neutralization assay**

The presence of neutralizing antibodies was assessed using a microneutralization 311 312 assay. The assay relies on the inhibition capacity of infection in an *in vitro* model 313 present in serum samples and employed recombinant vesicular stomatitis virus (rVSV) pseudovirus particles expressing the protein from the ancestral Wuhan-1 314 strain, Alpha, Delta, Beta, and the Omicron subvariants BA.2 (clone 1) and BA.5 315 (clone 4) (VSV-eGFP-SARS2) kindly provided by Dr. Sean Whelan (Washington 316 University, USA). The cellular model used to assess the inhibition capacity was the 317 Vero E6 cell line (The American Type Culture Collection (ATCC) CRL-1586, 318 Manassas, VA, USA), which is susceptible to infection as it expresses the 319 recognition receptors for the SARS-CoV-2 spike protein. 320

Before performing the assay (previously validated and established as an analytical 321 method), all serum samples were inactivated at 56 °C for 30 minutes. In 96-well 322 plates, 1.3 x 10<sup>4</sup> Vero E6 cells (ATCC, Manassas, VA, USA) per well were seeded 323 and incubated for 24 hours at 37 °C, 5% CO<sub>2</sub>, allowing them to reach 85% 324 325 confluence. Next, serum samples were serially diluted 1:2 in FBS-free Eagle's minimal essential medium (EMEM: Rahway, New Jersey, USA) in duplicate, starting 326 with a 1:20 dilution up to 1:1280. Diluted samples were mixed with the concentration 327 of particles of VSV-SARS-CoV-2 S pseudoviruses from the ancestral strain and the 328 aforementioned variants, capable of causing cellular damage at 50% (50% tissue 329 culture infectious dose, TCID<sub>50</sub>). The mixture was incubated for 60 minutes at 37 °C, 330 5% CO<sub>2</sub>. Then, each serum dilution was transferred to a parallel plate containing 331 Vero E6 cells and incubated for 72 h at 37 °C, 5% CO<sub>2</sub>. 332

After the incubation period, 3.7% formaldehyde was added and incubated for 30-40 333 minutes at room temperature. The plates were washed twice with PBS, and the 334 recording and analysis of the plates was carried out by optical microscopy, 335 documenting the presence or absence of damage to the monolaver, known as 336 cytopathic effect, at each dilution of the different serum samples. These values were 337 used to calculate the 50% protection level by applying the Spearman-Karber Method, 338 obtaining the 50% inhibitory dilution ( $ID_{50}$ ) and the protective titer of each sample. 339 The upper and lower detection limits for neutralizing activity are  $ID_{50} > 1.6$  and a titer 340 > 1:40 (initial dilution). Each assay included negative and positive infection controls 341 (uninfected cells and infection control inoculated with the reporter vector VSV-eGFP-342 343 SARS2 and the subvariants in a suspension containing 100 TCID<sub>50</sub>). Titers < 1:40(initial dilution) are reported with a value of 20 for statistical analysis. 344

#### 345 **Evaluation of cytokines in cell culture supernatants**

PBMCs were resuspended at a concentration of 2 x  $10^6$  cells/mL in CTS OpTmizer medium (GIBCO, California, USA). Duplicate samples of 2 x  $10^5$  cells/well were plated in 96-well plates and stimulated with 5 µg/mL of the spike protein subunit 1

(RayBiotech, Peachtree Corners, GA), using culture medium as a negative control. 349 350 After 18 hours of culture, the supernatant was collected, aliquoted, and stored at -20 °C until use for cytokine determination. Subsequently, the supernatants were thawed 351 and centrifuged at 14,000 rpm for 10 minutes, and cytokine concentrations were 352 measured using the Th1/Th2 Bio-Plex kit (BIO-RAD, California, USA). This kit allows 353 the guantification using the Bio-Plex 200 system and Bio-Plex Manager 6.1 software 354 (BIO-RAD, California, USA). Values were extrapolated from a concentration curve 355 and expressed in pg/mL. 356

# 357 Hemagglutination inhibition antibody assay for Newcastle disease virus (NDV)

358 A hemagglutination inhibition assay was performed to assess the presence of inhibitory antibodies against specific hemagglutination of NDV. This method, 359 adapted from the original avian sera procedure, was implemented and validated in 360 our group for human serum analysis. The procedure utilized a system with 1% avian 361 erythrocytes and eight hemagglutinant units (8 HAU/mL) of inactivated NDV antigen 362 (AqNDV, DCV Inc. Lot: 23920103). Briefly, serum samples were inactivated for 30 363 minutes at 56 °C: 100 µL of each sample underwent pre-absorption with an equal 364 volume of a 5% avian erythrocyte suspension and incubated overnight (16-18 h) at 365 2-8 °C. Next, the samples were centrifuged at 1,500 x g for 60 seconds, and the 366 supernatants were collected and stored at -20 °C until use. 367

In 96-well round-bottom plates, 25 µL/well of pre-absorbed serum samples were 368 placed in duplicate, and serial 1:2 dilutions were made (starting with a 1:8 dilution, 369 subsequent dilutions included 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, and 1:1,024). 370 Subsequently, 25 µL/well of AqNDV suspension adjusted to 8 HAU/mL was added. 371 and the samples were incubated (inhibition process) for 30 minutes at room-372 temperature (19-25 °C). Then, 25 µL of 1% avian erythrocyte suspension was added 373 and incubated for 40 minutes at room temperature (19-25 °C). The interpretation of 374 the plates was performed by placing them at a 45° position to observe the 375 precipitated erythrocytes flowing (teardrop formation). The technique's limit of 376 detection was a titer of 1:4, and the positive cutoff limit started from the titer of 1:8. 377 Samples that did not show inhibitory activity or whose activity was below the 1:4 378 dilution were assigned the value of the 1:2 dilution, corresponding to the immediately 379 preceding dilution (15,16). 380

### 381 Statistical analysis

To outline the demographic characteristics of the study population, measures of central tendency and dispersion were utilized for continuous variables, while proportions were employed for discrete or categorical variables. Continuous variables underwent analysis using one-way ANOVA and students' t-tests, whereas non-parametric tests were applied to discrete variables.

For safety assessments, the z-test was employed to compare proportions between treatment groups in the context of vaccine versus placebo, and the chi-square test was used for comparisons involving administration routes, vaccine, or placebo.

Individual antibody titers were quantified as the highest dilution titer that elicited a positive signal. Concurrently, the T-cell response was assessed by determining the concentration of cytokine-producing cells after stimulation with the spike subunit 1 protein following an 18-hour incubation period. The population results were characterized by a geometric mean (GM) and a 95% confidence interval.

#### 395 Results

From November 23, 2022, to July 24, 2023, 1,221 volunteers underwent eligibility
assessments, and the distribution of recruited volunteers is depicted in Figure 1.
Various research sites across different states of Mexico participated in volunteer
recruitment, including Mexico City (Investigación en Salud (CAIMED), S. A. de C. V.,
Unidad de Medicina Familiar No. 20 IMSS, CEMDEC S.A de C.V., and Unidad
Clínica Farmacológica Bioemagno S.A. de C.V.) and Oaxaca (Oaxaca Site
Management Organization (OSMO) S.C.).

Of the 1,221 volunteers initially screened, 1,011 participants did not meet the eligibility criteria during their first visit. The remaining 210 participants underwent assessment against both inclusion and exclusion criteria. During the second visit, 52 participants were excluded for not meeting the eligibility and inclusion criteria as described earlier. Therefore, the final cohort of participants comprised 158 individuals who were then randomized to receive either the AVX/COVID-12 vaccine or a placebo. The administration routes included IM and IN (Figure 1A).

In the AVX/COVID-12 vaccine group, 41 participants received IM immunization, 410 411 while 40 received IN. Five participants from the IM group and four from the IN group 412 withdrew from the study, resulting in 36 participants in each analyzed subgroup. In the placebo group, 40 participants were assigned to IM and 37 to IN administration. 413 Subsequently, participants from the placebo group (36 from the IM group and 35 414 from the IN group) were inoculated with the AZ/ChAdOx-1-S vaccine 14 days after 415 initially receiving the placebo; 7 participants from the IM group and six from the IN 416 group withdrew from the study. A total of 136 participants completed the study 417 418 (Figure 1B).

There were no statistically significant differences in age, gender, body mass index, or comorbidities between the IM and IN vaccinated groups and their respective placebo groups, except for race between the AVX/COVID-12 IM vaccinated group and its placebo (p=0.012) (Table 1).

In Mexico, various vaccines, including adenoviral vectors (AstraZeneca, CanSino,
Johnson & Johnson, Sputnik V), inactivated viruses (Sinovac), and mRNA (PfizerBioNTech), were employed for the national vaccination campaign. Therefore, an

additional inclusion criterion during the recruitment phase was completing the
primary vaccination series with any of the mentioned vaccines. A comparable
number of individuals with a similar history of prior vaccination were enrolled in each
group. No statistically significant differences were observed between the groups
regarding the history of previous SARS-CoV-2 vaccination, indicating a comparable
proportion of subjects vaccinated with various vaccine technologies (Table 2).

#### 432 Safety after vaccination with AVX/COVID-12

AEs were documented in subjects receiving IM AVX/COVID-12 (n=41), IM placebo (n=40), IN AVX/COVID-12 (n=40), and IN placebo (n=37) (total subjects 158). At day 28, IM and IN placebo group subjects received the AZ/ChAdOx-1-S vaccine, and AEs were recorded (n=71). Therefore, AEs were documented for 158 subjects receiving IM or IN AVX/COVID-12 vaccine and placebo groups, in addition to 71 subjects from the IM and IN placebo group who received the AZ/ChAdOx-1-S vaccine, making a total of 229 subjects (Tables 1S).

From the 229 subjects analyzed, 186 subjects reported AEs, with 38 belonging to 440 the group that received the AVX/COVID-12 vaccine IM and 31 from the IM placebo 441 group. Furthermore, 36 individuals came from the group that received the 442 AVX/COVID-12 vaccine IN, and 29 subjects received the IN placebo. Considering 443 the number of subjects recruited for each group that received the vaccine IM 444 administration (vaccine or placebo), it was observed that 92.68% of participants who 445 received the AVX/COVID-12 vaccine reported AEs, while the percentage for the IM 446 placebo group was 77.5%. This difference in proportions for both groups was 447 statistically significant, with a higher proportion of affected subjects in the 448 AVX/COVID-12 vaccine group (Figure 2A). Analyzing the groups that received the 449 AVX/COVID-12 vaccine and placebo IN, it was observed that 90% and 78.37% of 450 subjects in these groups reported adverse events, respectively. The difference 451 between these proportions was not statistically significant (Figure 2A). 452

After completing the follow-up period and unblinding the study, subjects initially receiving the placebo were administered a booster with the AZ/ChAdOx-1-S vaccine. The proportion of subjects reporting any AEs in the group that received the AVX/COVID-12 vaccine was significantly higher than the group that received the AZ/ChAdOx-1-S vaccine (Figure 2A). No significant differences were observed in the proportions of both groups when AEs were analyzed and grouped by severity.

459 Special interest local AEs reported at 7 days post-immunization, categorized by the number of affected subjects, were recorded (Table 2S). About, 19.21% of the study 460 participants reported being affected by at least one of these events. Specifically, for 461 each study group, this corresponds to 41.46% for the AVX/COVID-12 IM group, 15% 462 for the IM placebo group, 17.5% for the AVX/COVID-12 IN group, 5.4% for the IN 463 placebo group, and 16.9% for the AZ/ChAdOx-1-S group. When comparing the 464 proportion of subjects affected by the total events (Table 2S), it was observed that 465 466 AVX/COVID-12 IM had a significantly higher proportion than IM placebo (p=0.008) and AZ/ChAdOx-1S vaccine (p=0.004). This pattern was also observed for mild
events, while for moderate and severe events, no statistically significant differences
were found among these groups (Table 2S).

We identified statistically significant differences in AEs related to local general disorders and administration site conditions when comparing the group receiving AVX/COVID-12 IM with the AZ/ChAdOx-1-S vaccine group (p=0.001). Additionally, when the AVX/COVID-12 vaccinated group was compared with the placebo group, statistically significant differences were also observed (p=0.003) (Figure 2B). General discomfort included symptoms such as injection site pain (Table 2S).

Similarly, we analyzed systemic AEs of special interest reported within 7 days after 476 the administration of the AVX/COVID-12 vaccine. About, 44.1% of the study 477 478 participants reported being affected by one of these events. Specifically, 58.53% corresponded to the IM AVX/COVID-12 group, 50% to the IM placebo group, 57.5% 479 to the IN AVX/COVID-12 group, 40.54% to the IN placebo group, and 26.76% to the 480 AZ/ChAdOx-1-S group (Table 3S). When comparing groups, it was observed that 481 the group receiving IM AVX/COVID-12 had a significantly higher proportion of 482 subjects affected by this type of event than the AZ/ChAdOx-1-S group (p=0.0009). 483 Analyzing events according to severity, a significant difference was found for mild 484 485 events (Table 3S).

Subsequently, an analysis of events classified by system organ class (SOC) and 486 preferred term (PT) for systemic AEs at 7 days post-immunization was performed 487 (Table 3S). This analysis shows that the group receiving IM AVX/COVID-12 had a 488 significantly higher proportion of subjects affected than the AZ/ChAdOx-1-S group 489 490 for mild disorders of the nervous system, particularly headache (p=0.006); mild gastrointestinal disorders, particularly odynophagia (p=0.01); and mild thoracic and 491 mediastinal respiratory disorders, particularly rhinorrhea (p=0.0009) (Figure 2C and 492 Table 3S). 493

In the comparison between IM AVX/COVID-12 and placebo, a statistically significant difference was observed in the proportion of subjects affected by general disorders and site administration alterations (p=0.05). When the AVX/COVID-12 vaccine was administered IN, a significantly higher proportion of subjects showed mild gastrointestinal disorders compared to the IN placebo group (p=0.03) (Figure 2C).

Finally, regarding AEs related to vaccination, 9.17% of subjects reported AEs (Table
4S). In particular, 14.63% of subjects in the IM AVX/COVID-12 group, 10% in the IM
placebo group, 7.5% in the IN AVX/COVID-12 group, 2.7% in the IN placebo group,
and 9.85% in the AZ/ChAdOx-1-S group were reported. When analyzing events by
SOC and PT, no statistically significant differences were observed despite variations
in the proportion of subjects affected (Figure 2D).

#### 505 AVX/COVID-12 induced binding and neutralizing antibody titers against 506 Wuhan-1 and SARS-CoV-2 variants of concern

507 The evaluation of antibody titers and their neutralizing capacity in sera from 508 AVX/COVID-12 vaccinated volunteers against the spike protein was conducted 509 using ELISA and the pseudovirus neutralization assay at 14 days post-immunization, 510 both for the total number of volunteers vaccinated with AVX/COVID-12 IM and for 511 subjects who did not develop COVID-19 during the initial 14 days of the study (Table 512 3). Subsequent assessments were carried out over one year in IM-vaccinated 513 subjects (Table 5S and 6S) and IN (Table 7S and 8S).

The antibody response was analyzed for a year following immunization with the 514 AVX/COVID-12 vaccine via intramuscular and intranasal routes. Significant 515 differences are observed at all time points for anti-spike IgG antibodies in vaccinated 516 participants: titers increased at all analyzed time points compared to baseline levels 517 (Figure 3A), with the highest levels observed on day 14 post-immunization, followed 518 by a gradual decline. Interestingly, a slight increase is observed on day 365, possibly 519 520 due to SARS-CoV-2 infections during participants' follow-up. When analyzing the population, excluding those who developed mild COVID-19 during the study period 521 (Figure 3B), a similar antibody kinetics was observed. Additionally, when analyzing 522 IgG anti-S titers in volunteers vaccinated IN, a comparable pattern is observed when 523 excluding subjects positive for COVID-19 (Figure 3B). 524

525 AVX/COVID-12 induced a  $\geq$  4-fold increase in anti-spike IgG titers in 73.7% of the subjects receiving IM immunization when compared to placebo (10%) (p<0.0001). 526 In contrast, individuals receiving the vaccine IN showed a  $\geq$  4-fold increase of 51.3%, 527 compared to 16.2% in the placebo group (p=0.001) (Figure 4A). Similarly, 76.5% of 528 subjects who did not experience COVID-19 in the first 14 days post-immunization 529 and received IM AVX/COVID-12 showed a  $\geq$  4-fold increase compared to 0% in the 530 placebo group (p<0.0001). Meanwhile, 48.6% of volunteers who received the 531 vaccine IN exhibited a  $\geq$  4-fold increase compared to 7.1% in the placebo group 532 (p<0.0001) (Figure 4B). 533

Subsequently, neutralizing antibody titers against SARS-CoV-2 Wuhan-1 and Alpha, 534 Beta, Delta, and Omicron BA.2 and BA.5 VOCs were analyzed. For the IM-535 administered AVX/COVID-12 vaccine, statistically significant differences in the 536 neutralizing antibody responses were observed when compared to the placebo in all 537 cases (Figure 5 and Table 5S). In contrast, in subjects who received IN immunization 538 with AVX/COVID-12, statistically significant differences in the neutralizing antibody 539 responses were only observed for Wuhan-1 and Alpha (Figure 5). In the case of 540 subjects who did not present COVID-19 in the first 14 days, all groups immunized 541 IM or IN showed statistically significant differences in the neutralizing antibody 542 543 responses when compared to the placebo group, except for the anti-BA.5 neutralizing responses in the IN immunized group (Figure 5 and Table 6S). 544

In addition, the proportion of subjects who exhibited a  $\ge$  2.5-fold increase in neutralizing antibody titers against Wuhan-1 and the aforementioned VOC was determined. For subjects who received AVX/COVID-12 IM immunization, the

proportions of those exhibiting a  $\geq$  2.5-fold increase in neutralizing antibody titers 548 549 range from 84.2% to 50% (Alpha > Wuhan-1 > Omicron BA.5 > Delta > Omicron BA.2 > Beta), compared with subjects who received IM placebo, where 35.9% to 550 12.8% exhibited a  $\geq$  2.5-fold increase in neutralizing antibody titers (p < 0.0001 to 551 0.003) (Figure 6A). For those vaccinated with AVX/COVID-12 IN, the percentage of 552 individuals who exhibited a  $\geq$  2.5-fold increase in neutralizing antibody titers ranges 553 from 82.1% to 35.9% (Wuhan-1 > Alpha > Omicron BA.5 > Beta > Omicron BA.2 > 554 Delta) (p > 0.0001 to 0.045), except for the anti-BA.5 neutralizing antibody response. 555 556 where no statistically significant differences with the placebo were observed (Figure 557 6A).

In the sub-analysis, only subjects who did not present with COVID-19 in the first 14 558 days post-immunization were considered. For subjects who received AVX/COVID-559 12 IM, the percentage of those exhibiting a  $\geq$  2.5-fold increase in neutralizing 560 antibody titers ranged from 85.3% to 44.1% (Alpha > Wuhan-1 > Omicron BA.5 > 561 Delta > Omicron BA.2 > Beta), compared with volunteers administered a placebo, 562 ranging from 35.9% to 12.8% (p > 0.0001 to 0.03). Among the group vaccinated IN, 563 the percentage of individuals who exhibited a ≥2.5-fold increase in neutralizing 564 antibody titers ranged from 81.1% to 32.4% (Wuhan-1 > Alpha > Omicron BA.5 > 565 Beta > Omicron BA.2 > Delta). However, except for of the anti-BA.5 neutralizing 566 antibody responses, no statistically significant difference was observed when 567 compared with the placebo group (Figure 6B). Nevertheless, it should also be noted 568 that the IN placebo control group presented an unusually higher rise of anti-BA.5 569 specific antibodies as compared to the other VOCs, perhaps indicative of a recent 570 infection. 571

# 572 Comparable IFN-γ positive cellular responses were identified among 573 participants immunized with AVX/COVID-12, regardless of the administration 574 route

IFN-y production was measured from supernatants of PBMCs obtained from 575 volunteers vaccinated IM or IN (Tables 5 and 6) with the AVX/COVID-12 vaccine. 576 Cells were collected on days 0, 14, 180, and 365 (Table 7) and stimulated in vitro 577 with purified SARS-CoV-2 spike protein subunit 1 (Wuhan-1). In the total vaccinated 578 individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation 579 (SARS-CoV-2 PCR+/- and/or COVID-19+/-) (Table 7), statistically significant 580 differences in IFN-y production were observed at day 365 for IM-vaccinated 581 individuals (p < 0.01) and at days 180 (p < 0.03) and 365 (p < 0.01) in IN-vaccinated 582 individuals (Figure 7A). 583

Meanwhile, in subjects who did not test positive for SARS-CoV-2 in a PCR test
and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 negative)
(Table 8), the response observed at day 365 was higher compared to the SARSCoV-2 PCR+/- and/or COVID-19+/- group for both IM and IN immunized individuals.
A trend towards increased IFN-γ concentration was evident in both IM and IN

589 immunized groups with the AVX/COVID-12 vaccine; however, no statistically 590 significant differences were observed (Figure 7B).

# Immunization with the AVX/COVID-12 vaccine induces notably low specific antibody titers against the NDV vector

593 To assess the immune response elicited against the NDV vaccine vector, we 594 evaluated the specific antibody titers exhibiting hemagglutination inhibition (HAI) 595 activity in serum samples from individuals participating in phase I and II studies.

- 596 No antibodies with specific HAI against NDV were detected in all serum samples from individuals who participated in the phase II study on day 0 of recruitment, before 597 598 the administration of the AVX/COVID-12 vaccine as a booster dose. Samples above 599 the cut-off threshold of 8 HAI titers were considered positive. On day 14 following the initial administration of the AVX/COVID-12 vaccine, only two samples displayed 600 titers above 8, indicating seroconversion. Meanwhile, on days 42 and 90, 4 and 3 601 out of 144 sera exhibited titers equal to or greater than 8, respectively. These results 602 demonstrate that the administration of the AVX/COVID-12 vaccine at a dose of 10<sup>8.0</sup> 603 604 EID<sub>50</sub>/dose via the IM route induces a low specific seroconversion to NDV (Figure 8). 605
- In addition, serum samples from individuals participating in phase I, who received 606 two doses of 10<sup>8.0</sup> EID<sub>50</sub>/dose of the AVX/COVID-12 vaccine, were analyzed. It was 607 observed that all serum samples were negative for specific antibodies to the NDV 608 vector before the first immunization via IN or IM administration. On day 14 after 609 immunization, only 1 sample was positive. Meanwhile, titers higher than 8 were 610 detected after the second application of the AVX/COVID-12 vaccine (Day 42). On 611 the 90th day of follow-up, only 4 out of 10 sera showed titers higher than 8. After one 612 year, volunteers received a third dose as a boost. Before boosting, only 6 volunteers 613 had antibody titers equal to or greater than 8. After boosting, 42 out of 43 samples 614 were positive, most showing low titers against NDV. Seroconversion slowly faded, 615 and on day 90 after the boost, only 28 samples showed low antibody titers (Figure 616 617 8). Collectively, the data reveal that the induction of NDV-specific antibodies is exceedingly low (less than 0.2%) in the studied population after a single dose of the 618 AVX/COVID-12 vaccine. Following the second and third immunizations. 619 seroconversion increased; nevertheless, antibody titers remained at a low level. It is 620 important to emphasize that the technique developed with highly sensitive. 621

### 622 **Discussion**

523 SARS-CoV-2 and its VOCs have had a staggering effect on human health 524 worldwide. Despite the development and rapid deployment of vaccines against 525 SARS-CoV-2, many countries, particularly low and middle-income countries, have 526 not yet met their vaccination needs. This underscores the urgency of establishing 527 vaccine development and production capabilities in these regions to contribute to a 528 quicker onset of global community immunity against severe disease. The periodic administration of booster doses emerges as an essential measure to sustain community immunity against severe disease, reducing the magnitude of future waves of COVID-19 and safeguarding vulnerable populations, including the elderly, immunocompromised individuals, and those with comorbidities (17).

In this phase II clinical trial, we assessed the safety and immunogenicity of the 633 AVX/COVID-12 vaccine as a booster dose in volunteers who had previously 634 received COVID-19 vaccines based on adenoviral technology, inactivated virus, or 635 mRNA technology and exhibited antibody titers lower than 1,200 U/mL. These titers 636 were considered sufficiently low to observe the booster effect induced by the IM or 637 IN administration of AVX/COVID-12. Recruitment presented particular challenges 638 due to the prevailing infections with Delta and Omicron variants (BA.1 to BA.5) in 639 Mexico at the time of the trial, resulting in a high prevalence of antibody titers in the 640 population (Figure 1S). 641

After screening 1,221 volunteers, we ultimately enrolled 158 subjects who met the 642 inclusion criteria (Figure 1). The IM or IN booster immunization with AVX/COVID-12 643 was safe and well-tolerated for all individuals analyzed; most of the AEs were mainly 644 mild, and fewer were of moderate extent (Figure 2A). The vaccine exhibited 645 appropriate tolerability, and its safety profile did not raise any concerns, irrespective 646 647 of the volunteers' initial vaccination history (Figure 2B-C). AEs potentially associated with the vaccine were also mild and occurred in a small number of the volunteers 648 (Figure 2D). Additionally, the safety profile of AVX/COVID-12 was similar to that 649 observed for AZ/ChAdOx-1-S (Figure 2), the most widely used vaccine in Mexico 650 and worldwide (18,19). 651

We observed a substantial increase in spike binding (Figures 3 and 4) and 652 neutralizing antibody titers (Figure 5) among all volunteers following booster doses 653 of AVX/COVID-12 administered through IM and IN routes. Specific anti-spike IgG 654 slowly decayed during the following six months, but titers remained high and 655 increased one year after vaccination, perhaps due to viral exposure (Figure 3). As 656 described above, the trial was performed during a pandemic infection wave: 657 therefore, some volunteers were infected (no hospitalizations or deaths were 658 observed). The antibody titer increase held true irrespective of the volunteers' initial 659 vaccination history, involving vaccines based on adenoviral technology, inactivated 660 virus, or mRNA technology. 661

In the case of influenza vaccines,  $a \ge 4$ -fold increase in HAI titers is considered a successful seroconversion (20), and neutralizing antibody titers have also been correlated with protection for SARS-CoV-2 (21). Here, we observed a high proportion of subjects who received the AVX/COVID-12 vaccine showing  $a \ge 4$ -fold increase in anti-S IgG titers. As anticipated, the IM route of immunization proved to be more efficient than the IN route in inducing serum antibody titers (Figure 4).

668 Real-world evidence indicates that first-generation vaccines, utilizing the spike 669 protein from the original Wuhan-1 strain, exhibit high effectiveness against the

severity of infection (intensive care unit (ICU) admission or death) caused by various 670 671 subvariants of Omicron. For instance, a full vaccination scheme with a booster from Moderna shows 95% effectiveness, Pfizer demonstrates 95-100% (22,23), while 672 AstraZeneca or Janssen exhibits 85-90% effectiveness (23). Additionally, the mRNA 673 vaccine BNT162b2 has been reported to be 84.9% effective in preventing intensive 674 care unit admission for COVID-19 in children and 95% in adolescents (24). Other 675 studies indicate a 90.9% effectiveness of this vaccine against hospitalization and 676 death caused by the Omicron BA.1 and BA.2 variants of SARS-CoV-2, while the 677 678 AZ/ChAdOx-1-S vaccine showed 82.3% effectiveness (25). Moreover, COVID-19 vaccines available in Mexico have been reported to significantly reduce the risk of 679 severe disease during the Omicron wave in the country (26). 680

- Our results are in concordance with these observations: AVX/COVID-12 induced 681 neutralizing antibody responses not only against the Wuhan-1 original strain but also 682 683 against the Alpha, Beta, Delta, and Omicron (BA.2 and BA.5) variants (Figure 5). It was particularly surprising to observe a higher proportion of individuals with  $a \ge 2.5$ 684 increase in neutralizing titers against the BA.5 compared to BA.2, despite 685 recruitment being performed during the BA.1-4 and BA.5 pandemic waves (Figure 686 1S). These responses might be explained by the generation of hybrid immunity 687 induced by the combination of infection and vaccination or vice versa (3,4). In 688 addition, a significant cross-reactive response of both antibodies and T cells 689 generated by infection or vaccination has been identified; in the case of hybrid 690 immunity, these cross-reactive responses are heightened and broadened (3,4,27-691 29). These findings align with the description of a large set of conserved epitopes in 692 the spike protein for both humoral and cellular responses among SARS-CoV-2 693 Wuhan-1 and VOCs, as well as SARS-CoV, MERS-CoV, and seasonal 694 695 coronaviruses, and even within all those in the Orthocoronavirinae group (30).
- Across all study groups, an increase in IFN-γ levels at later time points is observed,
   suggesting a potential response to infections during the study (Figure 6). This
   phenomenon could be explained by the development of hybrid immunity, where the
   cellular response, through constant restimulations, may enhance both the magnitude
   of effector capacity (cytotoxicity and cytokine production) and the long-term memory
   response (31,32).
- We observed a tendency toward a more pronounced IFN-y response in individuals 702 who recovered from the infection (Figure 7). This response can be attributed to the 703 development of antigen-specific T cells and memory cells targeting viral antigens of 704 the virus, as the antigen-specific stimulation utilizes the spike protein of the virus. 705 706 We have found that these cells can persist in circulation despite decreasing antibody titers. Our study shows lower antibody titers at 180 and 365 days compared to those 707 observed 14 days after the first immunization (Figures 3 and 7). This increase might 708 also be attributed to continuous, asymptomatic contact with SARS-CoV-2, implying 709 710 the observed re-stimulation at day 365 (Figures 3 and 7). It is crucial to note the 711 study's limitation in quantifying IFN-y using BioPlex, which analyzes IFN-y

production derived from PBMCs stimulated with the spike protein, including natural
 killer cells (NK), CD4+ and CD8+ T cells, and monocytes.

A significant concern when using vector vaccines is the potential development of immune responses against the vector that could hinder its use in further immunizations. In this sense, it is essential to note that seroconversion against the NDV vector was almost absent after one or two immunizations, and the three-dose immunization scheme induced low and transient antibody titers (Figure 8). This suggests that the AVX/COVID-12 vaccine could be used repeatedly without losing efficacy.

### 721 Conclusions

722 The administration of the AVX/COVID-12 "Patria" vaccine as a booster dose, either 723 IM or IN, was deemed safe and well-tolerated. This resulted in the extension of 724 immune responses, not only against the Wuhan-1 original strain but also against other VOCs. The vaccine effectively enhanced preexisting immune responses, 725 726 supporting its use for boosting vaccination programs to expand and sustain 727 community immunity against severe outcomes in the population. These compelling findings strongly advocate incorporating AVX/COVID-12 as an additional booster 728 729 dose for the general population.

# 730 Acknowledgments

731 From CONAHCYT, we acknowledge María Elena Álvarez-Buylla Roces and Delia 732 Aideé Orozco Hernández for their role as an inter-institutional liaison and overall 733 facilitation of proceedings, committee evaluations, sanitary setup, and follow-up of 734 trial design approvals, evaluations, and progress. We additionally acknowledge the 735 broader support from various teams within all the clinical research sites and iLS 736 Clinical Research S. C., particularly Gabriela Rosas, Daniela Castro, Claudia 737 Aquilar, Roman Jarosch, and Alejandro Arias. From Laboratorio Avi-Mex, S. A. de C. V., we acknowledge the following people for their operative support: Bernardo 738 Lozano Alcántara, Alejandro Ruiz, Rosalba Rodríguez, Leticia Espinosa Gervasio, 739 Rodrigo Yebra Reves, Vanessa Escamilla Jiménez, Jaime Becerra Jiménez, Lorena 740 Juárez Pedraza, Sandra Yuridia Ang Tinajero, Avelia Ariadna Cuevas Cifuentes, 741 742 Juan Pablo Robles Álvarez, Avirán Almazán Gutiérrez, Aurora Betsabé Gutiérrez Balderas, Merlenne Rubio Díaz, and Guadalupe Aguilar Rafael. From INER, we 743 744 acknowledge the following people for their technical support: Liliana Figueroa Hernández, Francisco Cruz Flores, Claudia Ivett Hernández Lázaro, María Angelica 745 Velázquez González, Jessica Romero Rodríguez, Dulce Cinthia Soriano 746 Hernández, Milton Nieto Ponce, Edgar Reyna, Itzel Corona, José E. Márguez, 747 Angelica Moncada, and Pablo Franco-Mendoza. We acknowledge Sean Whelan 748 from the Icahn School of Medicine at Mount Sinai. From Instituto Politécnico 749 Nacional, Escuela Nacional de Ciencias Biológicas, we acknowledge Sonia Mayra 750 Pérez Tapia, Alexis Gabriel Suárez Gómez, and Sandra Comparán Alarcón. 751

#### 752 Funding:

The funding for the clinical study was provided by the National Council for 753 Humanities, Science and Technology (CONAHCYT, México), except for all the 754 production and vaccine product supply, which was funded solely by Laboratorio Avi-755 Mex, S. A. de C. V. (Avimex). CONAHCYT did not participate in the trial design but 756 did evaluate it and approved the project through their National Committee for 757 758 Science, Technology and Innovation in Public Health. Funding was managed by Avimex and used to pay for all laboratory tests, clinical sites, and clinical 759 professionals. CONAHCYT also facilitated the identification, purchase, and 760 importation of certain supplies and the communication with other entities of the 761 Federal Mexican Government to facilitate the study. 762

#### 763 **Conflict of interest:**

The vaccine candidate administered in this study was developed by faculty members 764 at the Icahn School of Medicine at Mount Sinai including P.P., F.K., and A.G.-S. 765 Mount Sinai is seeking to commercialize this vaccine: therefore, the institution and 766 its faculty inventors could benefit financially. The Icahn School of Medicine at Mount 767 Sinai has filed patent applications relating to SARS-849 CoV-2 serological assays 768 (USA Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503, and 769 63/024,436) and NDV-based SARS-CoV-2 vaccines (USA Provisional Application 770 Number: 63/251,020) which list F.K. as co-inventor. A.G.-S. and P.P. are co-771 inventors in the NDV-based SARS-CoV-2 vaccine patent application. Patent 772 applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount 773 Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-774 775 2 and another company, CastleVax, to commercialize SARS-CoV-2 vaccines. F.K., P.P., and A.G.-S. serve on the scientific advisory board of CastleVax and are listed 776 as co-founders of the company. F.K. has consulted for Merck, Segirus, Curevac, and 777 Pfizer, and is currently consulting for Gritstone, Third Rock Ventures, GSK, and 778 Avimex. The F.K. laboratory has been collaborating with Pfizer on animal models of 779 SARS-CoV-2. C.L.-M. has consulted for AstraZeneca. The A.G.-S. laboratory has 780 received research support from GSK, Pfizer, Senhwa Biosciences, Kenall 781 Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills 782 Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, 783 Model Medicines, Atea Pharma, Applied Biological Laboratories, and Merck. A.G.-784 785 S. has consulting agreements for the following companies involving cash and/or stock: Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, 786 Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, 787 CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, and Prosetta. 788 A.G.-S. has been an invited speaker in meeting events organized by Segirus, 789 Janssen, Abbott, and AstraZeneca. PP has a consulting agreement with Avimex. 790

791 Members of Avimex developed the live vaccine used in this study. Avimex filed 792 patent applications with Mount Sinai and CONAHCYT. M.T., D.S.-M., C.L.-M.,

H.E.C.-C., F.C.-P., G.P.D.L., and B.L.-D. are named as inventors on at least one of
those patent applications. The clinical study was entirely performed in Mexico, and
Mount Sinai had no role in it. The rest of the participants are employees of their
corresponding institutions and declare no competing interests.

# 797 **Ethical responsibilities:**

The protocol was approved by the ethics, research, and biosafety committees of each clinical research site, National Committee for Science, Technology and Innovation in Public Health of the National Council for Humanities, Science and Technology (CONAHCYT), and also by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS, Mexico) as a regulatory agency.

# 803 **Protection of humans and animals:**

No animals were used in this study. The protocol was designed to comply with the ethical principles of the Helsinki Declaration, Good Clinical Practices, and the applicable Mexican law.

# 807 **Data sharing:**

The protocol was registered in the National Registry of Clinical Studies under 808 number RNEC2021-AVXSARSCoV2VAC002 and published under NCT05205746. 809 810 Individual de-identified participant data will not be shared beyond the limits permitted by the informed consent and Mexican law. Specifically, this includes the sharing of 811 the study protocol, statistical analysis plan, informed consent form, and approved 812 813 clinical study report. Additionally, other de-identified data allowed under the informed 814 consent and Mexican law may be shared. The data will be made available 815 immediately upon publication and for 12 months thereafter. Access to the data will be granted solely to investigators with methodologically sound proposals, subject to 816 authorization by an independent review committee and the ethics committees 817 involved in approving the protocol. If required by law, authorization from the Federal 818 Commission for the Protection against Sanitary Risks (COFEPRIS) in Mexico will 819 also be obtained. Any use of the data must strictly adhere to the authorized purposes 820 outlined during the approval process. 821

# 822 Privacy rights and informed consent:

Informed Consent formats were provided and signed by all participants under Good
Clinical Practices and Mexican law. Personal data is confidential, and subjects are
not identified personally. Their data was analyzed and duly de-identified.

826

### 827 References

- 1. COVID-19 cases | WHO COVID-19 dashboard [Internet]. [cited 2024 Jan
- 18]. Available from: https://data.who.int/dashboards/covid19/cases?n=c

830 831 832	2.	Global Dashboard for Vaccine Equity - UNDP Data Futures Platform [Internet]. [cited 2023 Jan 5]. Available from: https://data.undp.org/vaccine- equity/
833 834 835	3.	Crotty S. Hybrid immunity. Science (80-) [Internet]. 2021 Jun 25 [cited 2024 Jan 18];372(6549):1392–3. Available from: https://www.science.org/doi/10.1126/science.abj2258
836 837 838	4.	Lasrado N, Barouch DH. SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds. J Infect Dis [Internet]. 2023 Nov 11 [cited 2024 Jan 18];228(10):1311–3. Available from: https://dx.doi.org/10.1093/infdis/jiad353
839 840 841 842	5.	Declaración de la OMS sobre la composición antigénica de las vacunas contra la COVID-19 [Internet]. [cited 2024 Jan 16]. Available from: https://www.who.int/es/news/item/13-12-2023-statement-on-the-antigen- composition-of-covid-19-vaccines
843 844 845 846 847 848	6.	Wichaidit M, Nopsopon T, Sunan K, Phutrakool P, Ruchikachorn P, Wanvarie D, et al. Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study. Lancet Reg Heal - Southeast Asia [Internet]. 2023 Jan 1 [cited 2024 Jan 18];8. Available from: http://www.thelancet.com/article/S2772368222001226/fulltext
849 850 851 852 853	7.	BoletínEpidemiológico Sistema Nacional de Vigilancia Epidemiológica Sistema Único de Información 2023   Secretaría de Salud   Gobierno   gob.mx [Internet]. [cited 2024 Jan 18]. Available from: https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema- nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-261547
854 855 856 857	8.	Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S, Lertjintanakit S, et al. Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2. Vaccines. 2021;9(5):1–9.
858 859 860 861	9.	Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science [Internet]. 2020 Sep 1 [cited 2023 Nov 15];369(6510):1501–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32703906/
862 863 864 865 866	10.	Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez L, Quezada-Monroy F, et al. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio [Internet]. 2021 Oct 1 [cited 2023 Jan 5];12(5). Available from: https://pubmed.ncbi.nlm.nih.gov/34544278/
867 868 869 870	11.	Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun [Internet]. 2021 Dec 1 [cited 2024 Jan 31];12(1). Available from:

- https://pubmed.ncbi.nlm.nih.gov/34707161/
- Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
  P, Carranza-Salazar DE, et al. Interim safety and immunogenicity results
  from an NDV-based COVID-19 vaccine phase I trial in Mexico. npj Vaccines
  [Internet]. 2023;8(1):67. Available from: https://doi.org/10.1038/s41541-02300662-6
- 877 13. Guidelines on clinical evaluation of vaccines: regulatory expectations, Annex
  878 1, TRS No 924 [Internet]. [cited 2023 Nov 15]. Available from:
  879 https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of880 vaccines-regulatory-expectations
- 14. Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al.
  SARS-CoV-2 vaccination induces mucosal antibody responses in previously
  infected individuals. Nat Commun 2022 131 [Internet]. 2022 Sep 1 [cited
  2024 Jan 18];13(1):1–8. Available from:
- https://www.nature.com/articles/s41467-022-32389-8
- Morokutti A, Redlberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N,
  Jungbauer A, et al. Validation of the modified hemagglutination inhibition
  assay (mHAI), a robust and sensitive serological test for analysis of influenza
  virus-specific immune response. J Clin Virol [Internet]. 2013 Apr [cited 2024
  Jan 29];56(4):323–30. Available from:
- 891 https://pubmed.ncbi.nlm.nih.gov/23375739/
- Kaufmann L, Syedbasha M, Vogt D, Hollenstein Y, Hartmann J, Linnik JE, et
  al. An Optimized Hemagglutination Inhibition (HI) Assay to Quantify
  Influenza-specific Antibody Titers. J Vis Exp [Internet]. 2017 Dec 1 [cited
  2024 Jan 29];2017(130):55833. Available from: /pmc/articles/PMC5755515/
- 896 17. Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS897 CoV-2 Control. JAMA [Internet]. 2020 Nov 24 [cited 2024 Jan
  898 18];324(20):2095–6. Available from:
- 899 https://jamanetwork.com/journals/jama/fullarticle/2772167
- 18. Covid World Vaccination Tracker The New York Times [Internet]. [cited2023 Nov 15]. Available from:
- https://www.nytimes.com/interactive/2021/world/covid-vaccinations tracker.html
- 904 19. COVID-19: dosis confirmadas de vacunas en México 2021 | Statista
   905 [Internet]. [cited 2023 Nov 15]. Available from:
- https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas covid-mexico/
- 908 20. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza
  909 Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced
  910 Protection. J Infect Dis [Internet]. 2011 Dec 15 [cited 2024 Jan
  911 191:204(12):1870, 85. Available from: https://dx.doi.org/10.1002/infdia/iir661
- 911 18];204(12):1879–85. Available from: https://dx.doi.org/10.1093/infdis/jir661

21. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et 912 al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine 913 efficacy clinical trial. Science (80-) [Internet]. 2022 Jan 7 [cited 2024 Jan 914 915 31]:375(6576):43–50. Available from: https://www.science.org/doi/10.1126/science.abm3425 916 Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. 917 22. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta 918 Symptomatic Infection and Severe Outcomes. JAMA Netw Open [Internet]. 919 2022 Sep 1 [cited 2024 Jan 31];5(9):e2232760-e2232760. Available from: 920 921 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796615 23. Paul P, El-Naas A, Hamad O, Salameh MA, Mhaimeed N, Laswi I, et al. 922 Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in 923 reducing infection, hospitalization, severity, and mortality compared to Delta 924 and other variants: A systematic review. Hum Vaccin Immunother [Internet]. 925 2023 [cited 2024 Jan 31];19(1). Available from: /pmc/articles/PMC10054360/ 926 24. Wu Q, Tong J, Zhang B, Zhang D, Xu J, Shen Y, et al. Real-world 927 Effectiveness of BNT162b2 in Children and Adolescents. medRxiv [Internet]. 928 2023 Jun 21 [cited 2024 Jan 18];2023.06.16.23291515. Available from: 929 https://www.medrxiv.org/content/10.1101/2023.06.16.23291515v2 930 25. Kirsebom FCM, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal 931 J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the 932 Omicron and Delta variants in England. Nat Commun 2022 131 [Internet]. 933 2022 Dec 12 [cited 2024 Jan 18];13(1):1–9. Available from: 934 935 https://www.nature.com/articles/s41467-022-35168-7 Hernández-Ávila M, Vieyra-Romero WI, Gutiérrez-Díaz H, Zepeda-Tello R, 936 26. Alpuche-Aranda C. Hernández-Ávila JE. et al. The Omicron wave in Mexico: 937 vaccine protection against progression to severe Covid-19 in SARS-CoV-2-938 infected workers. Salud Publica Mex [Internet]. 2024 [cited 2024 Jan 939 18];66(1, ene-feb):85–94. Available from: 940 https://www.saludpublica.mx/index.php/spm/article/view/15125 941 Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. 942 27. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and 943 uninfected controls. Nat 2020 5847821 [Internet]. 2020 Jul 15 [cited 2024 944 945 Jan 18];584(7821):457–62. Available from: https://www.nature.com/articles/s41586-020-2550-z 946 Stamatatos L. Czartoski J. Wan YH. Homad LJ. Rubin V. Glantz H. et al. 947 28. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by 948 SARS-CoV-2 infection. Science (80-) [Internet]. 2021 Jun 25 [cited 2024 Jan 949 18]:372(6549):1413-8. Available from: 950 https://www.science.org/doi/10.1126/science.abg9175 951 29. Revnolds CJ. Pade C. Gibbons JM. Butler DK. Otter AD. Menacho K. et al. 952 Prior SARS-CoV-2 infection rescues B and T cell responses to variants after 953

- 954 first vaccine dose. Science (80- ) [Internet]. 2021 Jun 25 [cited 2024 Jan
- 955 18];372(6549):1418–23. Available from:
- 956 https://www.science.org/doi/10.1126/science.abh1282
- 30. Singh G, Abbad A, Kleiner G, Srivastava K, Gleason C, Carreño JM, et al.
  The post-COVID-19 population has a high prevalence of cross-reactive
  antibodies to spikes from all Orthocoronavirinae genera. MBio [Internet].
- antibodies to spikes from all Orthocoronavirinae genera.
  2024 Jan 16 [cited 2024 Jan 19]: Available from:
- 961 https://journals.asm.org/doi/10.1128/mbio.02250-23
- 31. Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding
  COVID-19. Immunity [Internet]. 2021 Jan 1 [cited 2023 Jul 11];54(1):14.
  Available from: /pmc/articles/PMC7749639/
- Guerrera G, Picozza M, D'Orso S, Placido R, Pirronello M, Verdiani A, et al.
  BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a
  stem cell memory phenotype. Sci Immunol [Internet]. 2023 Jul
- 968 12;6(66):eabl5344. Available from:
- 969 https://doi.org/10.1126/sciimmunol.abl5344

970

971



**Figure 1. Screening and randomization of the participants.** A) Flowchart depicting participant screening, randomization, and distribution across various experimental groups throughout the study. B) Scheme illustrating the distribution of volunteers into groups and post-boosting monitoring.



Figure 2. Adverse events 7 days after vaccination with AVX/COVID-12 or AZ/ChAdOx-1-S. Adverse events in participants following vaccination with the AVX/COVID-12 vaccine, compared with the AZ/ChAdOx-1-S vaccinated and placebo group. A) Percentage of participants affected by adverse events classified by severity; B) Local adverse events of special interest; C) Systemic adverse events of special interest; and D) Adverse events potentially associated with the vaccine. p-value calculated from a comparison of proportions (Z-test). Statistically significant differences were observed with p-values:  $p \le 0.05$ .



Days after vaccination with AVX/COVID-12

Figure 3. Intramuscular and intranasal administration of the AVX/COVID-12 vaccine resulted in comparable anti-spike IgG antibody titers. Geometric means and confidence intervals of serum antibody titers post-vaccination with the AVX/COVID-12 vaccine were assessed A) intramuscularly (red circles) and intranasally (blue triangles) throughout the study and B) intramuscularly (red circles) and detected during the study follow-up period. P values were calculated by comparing the geometric means using the Wilcoxon signed-rank test with variables presented on a logarithmic scale.



Figure 4. Proportion of subjects with a  $\geq$ 4-fold increase in anti-spike IgG antibody titers. (A) All enrolled study participants and (B) subjects where SARS-CoV-2 infection was not detected during the 14 days after vaccination. P values were calculated using Fisher's exact test.



Figure 5. Comparison of neutralizing antibody titers against SARS-CoV-2 variants of concern (VOC) in subjects 14 days after receiving AVX/COVID-12 or placebo. Geometric mean comparison of neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) VOCs in volunteers after 14 days of receiving AVX/COVID-12 intramuscular (IM) (closed red circles) or IM

placebo (open red circles) and AVX/COVID-12 intranasal (IN) (closed blue triangles) or IN placebo (open blue triangles). Analysis was performed on the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR+/-), or in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). Mann–Whitney U test with variables presented on a natural logarithmic scale.



Figure 6. Proportion of subjects with a ≥2.5-fold increase in neutralizing titers against SARS-CoV-2 variants of concern induced by AVX/COVID-12 immunization. Neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) variants of concern were measured 14 days after intramuscular (IM) (red closed bars) or intranasal (IN) (blue closed bars)

AVX/COVID-12 administration, and IM (striped red bars) or IN (striped blue bars) placebo administration. A) In the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR +/-) or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). P values were calculated using Fisher's exact test.



**Figure 7. Cellular responses induced by the AVX/COVID-12 Vaccine.** IFN-γ production was measured from peripheral blood mononuclear cells (PBMCs) of volunteers immunized intramuscularly (IM) with red circles or intranasally (IN) with blue triangles using the AVX/COVID-12 vaccine at the indicated time points. Volunteers' PBMCs were stimulated for 18 hours with purified SARS-CoV-2 S1 protein (Wuhan-1), and IFN-γ production was measured from cell culture supernatants using BioPlex. A) In the total vaccinated individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation (SARS-CoV-2 PCR+/- and/or COVID-19+/-), or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 Negative). Significant differences were calculated with the Wilcoxon signed-rank test.



Days after vaccination with AVX/COVID-12

**Figure 8. Immunization with the AVX/COVID-12 vaccine induces notably low specific antibody titers against the NDV vector.** Analysis of hemagglutination inhibition antibody (HAI) titers specific to the Newcastle disease virus (NDV) vector in sera from individuals who received the AVX/COVID-12 vaccine as a booster dose in the phase II clinical trial (green circles, n=154) or as part of the primary immunization scheme with two doses on day 0 and a booster on day 21 (orange circles, n=10), and after a homologous booster dose on day 365 in the phase I clinical trial (red circles, n=43). Samples above the cut-off threshold of 8 HAI titers were considered positive (doted line).



Supplementary Figure 1. COVID-19 incidence in Mexico during the recruitment and monitoring of the study participants.

#### Tables

#### Table 1. Demographic characteristics of phase II study volunteers.

	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value
Volunteers (n)	41	40		40	37	
Age, mean (SD)	39.8 (11.9)	33.5 (11.3)	0.01	37.8 (13.5)	36.6 (13.8)	0.65
Age groups (years old)						
< 20	-	-	0.15	1 (2.5)	1 (2.7)	0.79
20 - 29	12 (29.27)	22 (55)		11 (27.5)	14 (37.84)	
30 - 39	7 (17.07)	6 (15)		12 (30)	8 (21.62)	
40 - 49	16 (39.02)	7 (17.5)		6 (15)	7 (18.92)	
50 - 59	3 (7.32)	3 (7.5)		7 (17.5)	4 (10.81)	
60 - 69	3 (7.32)	2 (5)		3 (7.5)	2 (5.41)	
70 - 79	-	-		-	1 (2.7)	
Gender, n (%)						
Female	21 (51.22)	23 (57.5)	0.57	19 (47.5)	16 (43.24)	0.70
Male	20 (48.78)	17 (42.5)		21 (52.5)	21 (56.76)	
MBI, mean (SD)	26.3 (6.0)	26.5 (5.1)	0.43	26.7 (6.1)	26.5	0.88
BMI classification						
Underweight	2 (4.88)	1 (2.5)	0.68	3 (7.5)	2 (5.41)	0.64
Normal	11 (26.83)	15 (37.5)		14 (35)	14 (37.84)	
Overweight	18 (43.9)	17 (42.5)		10 (25)	13 (35.14)	
Obesity	10 (24.39)	7 (17.5)		13 (32.5)	8 (21.62)	
Race, n (%)						
White	3 (7.32)	2 (5)	0.012	1 (2.5)	2 (5.41)	0.14
Amerindian	10 (24.39)	2 (5)		10 (25)	3 (8.11)	
Mexican Mestizo	27 (65.85)	28 (70)		26 (65)	31 (83.78)	
Other	1 (2.44)	8 (20)		3 (7.5)	1 (2.7)	
Comorbidities, n (%)						
0	38 (92.68)	39 (97.5)	0.31	37 (92.5)	33 (89)	0.59
1	3 (7.32)	1 (2.5)	0.34	3 (7.5)	4 (10)	0.69
Systolic arterial hypertension	2 (4.87)	1 (2.5)	0.57	2 (5)	2 (5)	1
Type 2 Diabetes Mellitus	-	-		1 (2.5)	-	NA
HIV	1 (2.44)	-	NA	-	2 (5)	NA

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; SD: Standard Deviation; BMI: Body Mass Index. Mann–Whitney's U test was conducted for median comparisons, and the Chi-Square test was used for categorical variables.

# Table 2. Prior history of SARS-CoV-2 vaccination among phase II participants at baseline.

	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value
Volunteers (n) Last vaccination schedule prior to the study, n (%)	41	40		40	37	
Adenoviral Vector	31 (75.6)	33 (82.5)	0.44	31 (77.5)	33 (89.2)	0.17
AstraZeneca	16 (39.02)	16 (40)	0.92	12 (30)	14 (37.84)	0.46

CanSino	4 (9.76)	4 (10)	0.97	5 (12.5)	8 (21.62)	0.28
Johnson & Johnson	1 (2.44)	-	N/A	1 (2.5)	-	N/A
Sputnik V	10 (24.39)	13 (32.5)	0.41	13 (32.5)	11 (29.73)	0.79
Inactivated Viruses						
Sinovac	6 (14.63)	4 (10)	0.52	5 (12.5)	3 (8.11)	0.52
mRNA						
Pfizer	4 (9.76)	3 (7.5)	0.71	4 (10)	1 (2.7)	0.19
A\/X· A\/X/CO\/ID-12·	PI · placebo:	IM· intram	iscular.	IN: intranasa	I SD Star	dard

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; SD: Standard Deviation; BMI: Body Mass Index. Mann–Whitney's U test was used for median comparisons, and the Chi-Square test was used for categorical variables.

Table 3. Proportion of subjects with an increase in neutralizing antibody titers against SARS-CoV-2 variants of concern 14 days after receiving AVX/COVID-12 or placebo.

All volunteers								
	IM AVX	IM PL	Valor p	IN AVX	IN PL	Valor p		
Subjects per group:	38	39	-	39	37	-		
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	30	7		32	9			
Wuhan-1								
Proportion	78.9%	17.9%	<0.0001	82.1%	24.3%	<0.0001		
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	21	7		14	6			
Delta								
Proportion	55.3%	17.9%	0.001	35.9%	16.2%	0.045		
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	32	10		30	11			
Alpha								
Proportion	84.2%	25.6%	<0.0001	76.9%	29.7%	<0.0001		
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	19	7		19	8			
Beta								
Proportion	50.0%	17.9%	0.003	48.7%	21.6%	0.012		
Number of subjects with a $\geq 2.5$ -fold								
increase in neutralizing titers against	19	5		16	6			
Omicron (BA.2)		Ū.			U U			
Proportion	50.0%	12.8%	< 0.0001	42.1%	16.2%	0.013		
Number of subjects with a $\geq 2.5$ -fold	001070			,.		0.0.0		
increase in neutralizing titers against	27	14		25	18			
Omicron (BA 5)		• •		20	10			
Proportion	71 1%	35.9%	0.002	65.8%	48.6%	0 102		
Porticipanto with a page	TIT TO				40.070	0.102		
Participants with a nega	tive SARS-C	50V-2 PCF	test in the	initial 14 0	lays.			
	IM AVX	IM PL	Valor p	IN AVX	IN PL	Valor p		
Subjects per group:	34	29		37	28			
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	26	3		30	6			
Wuhan-1								
Proportion	76.5%	10.3%	<0.0001	81.1%	21.4%	<0.0001		
Number of subjects with a ≥2.5-fold								
increase in neutralizing titers against	18	4		12	2			
Delta								
Proportion	52.9%	13.8%	<0.0001	32.4%	7.1%	0.013		
Number of subjects with $2.52.5$ fold								
increase in poutralizing titors against	20	6		20	0			
Alpha	23	0		23	0			
Proportion	05.00/	00 70/	0.000	70 404	00.00 <i>/</i>	0.0004		
	85.3%	20.7%	<0.0001	78.4%	28.6%	<0.0001		
Number of subjects with a ≥2.5-fold	15	3		17	2			

increase in neutralizing titers against Beta Proportion	44 1%	10.3%	0.003	45 9%	7 1%	0 001
Number of subjects with $c > 2 E$ fold	11.170	10.070	0.000	10.070	7.170	0.001
increase in neutralizing titers against BA.2	17	0		14	1	
Proportion	50.0%	0.0%	<0.0001	38.9%	3.6%	<0.0001
Number of subjects with a ≥2.5-fold increase in neutralizing titers against BA.5	25	8		23	14	
Proportion	73.5%	27.6%	<0.0001	63.9%	50.0%	0.195

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; P values are derived from Fisher's exact test.

# Table 4. Proportion of subjects with an increase in neutralizing antibody titers at 14 days post-immunization against different variants of SARS-CoV-2.

	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value
Subjects per group	38	39		39	37	
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	30	7		32	9	
against Wuhan-1 variant						
Proportion	78.9%	17.9%	<0.0001	82.1%	24.3%	<0.0001
Number of subjects with ≥2.5-fold		-			0	
increase in neutralizing antibody titers	21	1		14	6	
against Deita Variant	EE 20/	17.00/	0.001	25.0%	16.00/	0.045
Proportion Number of subjects with $>2.5$ fold	55.3%	17.9%	0.001	35.9%	16.2%	0.045
increase in poutralizing antibody titors	22	10		20	11	
angingt Alpha variant	32	10		30	11	
Proportion	84 2%	25.6%	<0.0001	76.9%	29.7%	<0.0001
Number of subjects with $>25$ -fold	04.270	20.070	20.0001	10.070	20.170	<b>LO.0001</b>
increase in neutralizing antibody titers	19	7		19	8	
against Beta variant		•			U U	
Proportion	50.0%	17.9%	0.003	48.7%	21.6%	0.012
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	19	5		16	6	
against BA.2						
Proportion	50.0%	12.8%	<0.0001	42.1%	16.2%	0.013
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	27	14		25	18	
against BA.5						
Proportion	71.1%	35.9%	0.002	65.8%	48.6%	0.102
Subjects w	ithout COVII	D-19 in the	e first 14 dag	ys		
	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value
Subjects per group	34	29	-	37	28	-
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	26	3		30	6	
against Wuhan-1 variant						
Proportion	76.5%	10.3%	<0.0001	81.1%	21.4%	<0.0001
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	18	4		12	2	
against Delta variant						
Proportion	52.9%	13.8%	<0.0001	32.4%	7.1%	0.013
Number of subjects with ≥2.5-fold						
increase in neutralizing antibody titers	29	6		29	8	
against Alpha variant						
Proportion	85.3%	20.7%	<0.0001	78.4%	28.6%	<0.0001

0.195
<0.0001
0.001

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; P values are derived from Fisher's exact test.

# Table 5. IFN- $\gamma$ secreted (pg/mL) by T lymphocytes, comparison on day 14 between AVX/COVID-12 and placebo.

All volunteers										
	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value				
Subjects	20	35		20	33					
GM	324.2	258.6		193.7	406.7					
CI	166.5 - 631.4	123.1 - 543.2	0.97	73 - 513.4	262 - 631.4	0.31				
	v	olunteers without	COVID-19 in t	he first 14 days						
	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value				
Subjects	17	27		19	27					
GM	280	168.6		175.5	358					
CI	133.3 - 588.1	71.2 - 399.2	0.71	64 - 481	220 -581	0.33				

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval. Comparisons of GM at day 14 between groups, p values were calculated using the Mann–Whitney's U test.

# Table 6. Proportion of subjects with an increase in IFN- $\gamma$ secretion by peripheral blood T lymphocytes in response to stimulation with the S protein of SARS-CoV-2.

All volunteers										
IM AVX IM PL p-Value IN AVX IN PL p-Value										
Subjects	19	35		17	32					
Number of subjects with an increase ≥1.25 in interferon-gamma-producing T lymphocytes	8	19		7	20					
Proportion	42.1%	54.3%	0.569	41.1%	62.5%	0.228				
Volunteers without COVID-19 in the first 14 days.										
	IM AVX	IM PL	p-Value	IN AVX	IN PL	p-Value				
Subjects	16	27		16	26					

Number of subjects with an increase ≥1.25 in interferon-gamma-producing	7	15		7	18	
T lymphocytes						
Proportion	43.7%	55.6%	0.537	43.7%	69.2%	0.121

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; p-values were calculated using the Fisher's exact test.

# Table 7. IFN- $\gamma$ secreted (pg/mL) by T lymphocytes in subjects vaccinated with AVX/COVID-12 throughout the study.

All volunteers AVX IM									
	Baseline	Day 14	Day 180	Day 365					
Subjects	24	20	39	21					
GM	235.8	324.2	867.1	1160.1					
CI	107.1 - 519.2	166.5 - 631.4	602 - 1249.1	746- 1804.1					
p-Value		0.99	0.09	0.01					
AVX IN									
	Baseline	Day 14	Day 180	Day 365					
Subjects	20	20	34	18					
GM	241.4	193.7	951.2	1011.3					
CI	81.75248 713.1	73 - 513.4	648.5 - 1395.3	642.2 - 1592.4					
p-Value		0.83	0.03	0.01					

AVX: AVX/COVID-12; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval. Comparison of GM using the Wilcoxon signed-rank test.

# Table 8. IFN- $\gamma$ secreted (pg/mL) by T lymphocytes in subjects without COVID-19 vaccinated with AVX/COVID-12 throughout the study.

	Volunteers	s without COVID-19 AVX IM	
	Día 14	Día 180	Día 365
Subjects	3	24	17
GM	744.6	842.6	974
CI	40.4 - 13715.6	496.9 - 1428.9	583.9 - 1624.7
		AVX IN	
	Día 14	Día 180	Día 365
Subjects	19	18	8
GM	175.5	895.7	1374.6
CI	64 - 481	493.1 - 1626.9	614.3 - 3075.7

AVX: AVX/COVID-12; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval.

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Subjects		41		40		40		37		71		229				
Any AE	Total	38	(92.68)	31	(77.5)	36	(90)	29	(78.37)	52	(73.23)	186	(81.22)	0.05	0.16	0.01
	МІ	38	(92.68)	31	(77.5)	36	(90)	29	(78.37)	51	(71.83)	185	(80.78)	0.05	0.16	0.008
	Мо	13	(31.7)	1	(2.5)	10	(25)	10	(27.02)	18	(25.35)	52	(22.7)	0.0005	0.83	0.46
	S	3	(7.31)	0	(0)	1	(2.5)	0	(0)	2	(2.81)	6	(2.62)	0.08	0.33	0.26
Pregnancy, puerperium, and perinatal diseases	Total	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Abortion	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Pregnancy	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Supplementary examinations	Total	4	(9.75)	0	(0)	2	(5)	1	(2.7)	0	(0)	7	(3.05)	0.04	0.60	0.007
	Mi	4	(9.75)	0	(0)	2	(5)	1	(2.7)	0	(0)	7	(3.05)	0.04	0.60	0.007
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Decrease in Glomerular Filtration Rate	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Elevation of Aspartate Aminotransferase	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Elevation of Cystatin C	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Elevation of Human Chorionic Gonadotropin	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Elevation of Lactate Dehydrogenase	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Elevation of Blood Pressure	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Elevation of Systolic Pressure	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Elevation of Alanine Aminotransferase	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18

# Table 1S. Proportion of affected subject by adverse events at 7 days post-immunization.

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	im az	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Infections and infestations	Total	36	(87.8)	15	(37.5)	29	(72.5)	13	(35.13)	37	(52.11)	130	(56.76)	0.0000	0.001	0.0001
	Mi	35	(85.36)	15	(37.5)	28	(70)	13	(35.13)	32	(45.07)	123	(53.71)	0.0000	0.002	0.0000
	Мо	4	(9.75)	0	(0)	5	(12.5)	2	(5.4)	7	(9.85)	18	(7.86)	0.04	0.27	0.98
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Dental Abscess	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Bronchitis	Mi	2	(4.87)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	4	(1.74)	0.15	0.33	0.27
COVID-19	Mi	26	(63.41)	9	(22.5)	18	(45)	11	(29.72)	19	(26.76)	83	(36.24)	0.0002	0.16	0.0001
COVID-19	Мо	1	(2.43)	0	(0)	3	(7.5)	0	(0)	1	(1.4)	5	(2.18)	0.32	0.08	0.69
Toothache	Mi	1	(2.43)	0	(0)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.32	0.29	0.18
Gastroenteritis	Mi	0	(0)	0	(0)	3	(7.5)	1	(2.7)	2	(2.81)	6	(2.62)		0.34	0.27
	Мо	0	(0)	0	(0)	1	(2.5)	1	(2.7)	0	(0)	2	(0.87)		0.95	
Gingivitis	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Hepatitis A	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Herpes Zoster	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	0.44
Bacterial Infection of Respiratory Tract	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
Respiratory Tract Infection	Mi	9	(21.95)	0	(0)	5	(12.5)	0	(0)	4	(5.63)	18	(7.86)	0.001	0.02	0.009
Upper Respiratory Tract Infection	Mi	5	(12.19)	4	(10)	4	(10)	0	(0)	11	(15.49)	24	(10.48)	0.75	0.04	0.63
Upper Respiratory Tract Infection	Мо	2	(4.87)	0	(0)	2	(5)	1	(2.7)	3	(4.22)	8	(3.49)	0.15	0.60	0.87
Urinary Tract Infection	Мо	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
Urinary Tract Infection	Mi	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
Dental Infection	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Dental Infection	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Vaginal Infection	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Influenza	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Pharyngitis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Onychomycosis	Mi	0	(0)	0	(0)	0	(0)	0	(0)	2	(2.81)	2	(0.87)			0.27
Osteomyelitis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Acute Otitis Media	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Acute Otitis Media	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Rhinitis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
Rhinitis	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Post-Acute COVID-19 Syndrome	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
American Trypanosomiasis	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Bacterial Vaginosis	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Benign, Malignant, and Unspecified Neoplasms (Cysts and Polyps)	Total	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Lipoma	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Traumatic injuries, poisonings, and complications of therapeutic	Total	3	(7.31)	4	(10)	3	(7.5)	1	(2.7)	5	(7.04)	16	(6.98)	0.66	0.34	0.99
procedures	Mi	2	(4.87)	4	(10)	3	(7.5)	1	(2.7)	4	(5.63)	14	(6.11)	0.37	0.34	0.86
	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Epicondylitis	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Dental Fracture	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
Sunstroke	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Injury	Mi	2	(4.87)	1	(2.5)	2	(5)	1	(2.7)	0	(0)	6	(2.62)	0.57	0.60	0.06
Traumatic Skin Injury	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Facial Traumatic Injury	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Animal Bite	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Chemical Burn	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Chemical Burn	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Thermal Burn	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		

															15.1	
SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Injection-Related Reaction	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
Medical and Surgical Procedures	Total	1	(2.43)	0	(0)	3	(7.5)	0	(0)	3	(4.22)	7	(3.05)	0.32	0.08	0.62
	Mi	1	(2.43)	0	(0)	3	(7.5)	0	(0)	3	(4.22)	7	(3.05)	0.32	0.08	0.62
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Dental Care	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Periodontal Surgery	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Tooth Extraction	Mi	0	(0)	0	(0)	2	(5)	0	(0)	1	(1.4)	3	(1.31)		0.16	0.44
Hysterectomy	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Removal of Intrauterine Contraceptive Device	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Cardiac Disorders	Total	0	(0)	0	(0)	1	(2.5)	1	(2.7)	2	(2.81)	4	(1.74)		0.95	0.27
	Mi	0	(0)	0	(0)	1	(2.5)	1	(2.7)	0	(0)	2	(0.87)		0.95	
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	2	(2.81)	2	(0.87)			0.27
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Arrhythmia	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Chest Pain	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Palpitations	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Tachycardia	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Skin and Subcutaneous Tissue Disorders	Total	0	(0)	5	(12.5)	3	(7.5)	0	(0)	8	(11.26)	16	(6.98)	0.01	0.08	0.03
	Mi	0	(0)	5	(12.5)	3	(7.5)	0	(0)	7	(9.85)	15	(6.55)	0.01	0.08	0.04
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Acne	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Dermatitis	Mi	0	(0)	2	(5)	2	(5)	0	(0)	2	(2.81)	6	(2.62)	0.14	0.16	0.27
Dermatitis	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Bruising	Mi	0	(0)	1	(2.5)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.30	0.33	
Erythema	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC PT		SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Granu	uloma	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Нурег	erhidrosis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Petec	chiae	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Prurit	tus	Mi	0	(0)	1	(2.5)	1	(2.5)	0	(0)	2	(2.81)	4	(1.74)	0.30	0.33	0.27
Disorders of system	of the blood and lymphatic	Total	2	(4.87)	3	(7.5)	3	(7.5)	3	(8.1)	0	(0)	11	(4.8)	0.62	0.92	0.06
		Mi	2	(4.87)	3	(7.5)	3	(7.5)	2	(5.4)	0	(0)	10	(4.36)	0.62	0.70	0.06
		Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Нурос	ochromic anemia	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Basop	philia	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Coag	gulopathy	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Eosin	nophilia	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Leuco	openia	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Lymp	phopenia	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Neutr	rophilia	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Neutro	ropenia	Mi	0	(0)	0	(0)	1	(2.5)	1	(2.7)	0	(0)	2	(0.87)		0.95	
Thron	mbocytosis	Mi	2	(4.87)	1	(2.5)	0	(0)	1	(2.7)	0	(0)	4	(1.74)	0.57	0.29	0.06
Thron	mbocytopenia	Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Reproductiv	ve and breast disorders	Total	5	(12.19)	2	(5)	1	(2.5)	3	(8.1)	7	(9.85)	18	(7.86)	0.24	0.26	0.70
		Mi	3	(7.31)	2	(5)	1	(2.5)	1	(2.7)	6	(8.45)	13	(5.67)	0.66	0.95	0.83
		Мо	1	(2.43)	0	(0)	0	(0)	2	(5.4)	2	(2.81)	5	(2.18)	0.32	0.13	0.90
		S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Dysm	nenorrhea	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	1	(1.4)	3	(1.31)	0.30	0.29	0.44
Dysm	nenorrhea	Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Vagin	nal bleeding	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Polyc	cystic ovaries	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
Breas	st cyst	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	im az	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Prostatitis	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Delayed menstruation	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Heavy menstrual bleeding	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Menstrual disorders	Mi	1	(2.43)	1	(2.5)	0	(0)	0	(0)	3	(4.22)	5	(2.18)	0.98		0.62
Menstrual disorders	Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	1	(1.4)	2	(0.87)		0.29	0.44
Ovarian cyst	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Varicocele	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Metabolic and Nutritional Disorders	Total	10	(24.39)	7	(17.5)	6	(15)	6	(16.21)	1	(1.4)	30	(13.1)	0.44	0.88	0.001
	Mi	10	(24.39)	7	(17.5)	6	(15)	6	(16.21)	1	(1.4)	30	(13.1)	0.44	0.88	0.001
	М	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Vitamin B12 Deficiency	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Vitamin D Deficiency	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Dyslipidemia	Mi	2	(4.87)	0	(0)	2	(5)	2	(5.4)	0	(0)	6	(2.62)	0.15	0.93	0.06
Hypercholesterolemia	Mi	2	(4.87)	2	(5)	3	(7.5)	1	(2.7)	0	(0)	8	(3.49)	0.97	0.34	0.06
Hyperglycemia	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Hypertriglyceridemia	Mi	3	(7.31)	4	(10)	1	(2.5)	3	(8.1)	0	(0)	11	(4.8)	0.66	0.26	0.02
Obesity	Mi	0	(0)	1	(2.5)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.30	0.33	
Insulin Resistance	Mi	2	(4.87)	0	(0)	0	(0)	0	(0)	0	(0)	2	(0.87)	0.15		0.06
Metabolic Syndrome	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Overweight	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Disorders of the ear and labyrinth	Total	1	(2.43)	0	(0)	2	(5)	0	(0)	0	(0)	3	(1.31)	0.32	0.16	0.18
	Mi	1	(2.43)	0	(0)	2	(5)	0	(0)	0	(0)	3	(1.31)	0.32	0.16	0.18
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Ear pain	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Ear disorder	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Vertigo	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Disorders of the immune system	Total	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Hypersensitivity	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Disorders of the nervous system	Total	17	(41.46)	16	(40)	16	(40)	16	(43.24)	17	(23.94)	82	(35.8)	0.89	0.77	0.05
	Mi	15	(36.58)	16	(40)	15	(37.5)	14	(37.83)	14	(19.71)	74	(32.31)	0.75	0.97	0.05
	Мо	6	(14.63)	1	(2.5)	2	(5)	4	(10.81)	3	(4.22)	16	(6.98)	0.05	0.34	0.05
	S	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Ageusia	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Anosmia	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Headache	Mi	14	(34.14)	14	(35)	15	(37.5)	14	(37.83)	12	(16.9)	69	(30.13)	0.93	0.97	0.03
Headache	Мо	5	(12.19)	1	(2.5)	1	(2.5)	4	(10.81)	3	(4.22)	14	(6.11)	0.09	0.13	0.11
Bruise	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Memory impairment	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Dizziness	Mi	0	(0)	3	(7.5)	0	(0)	1	(2.7)	1	(1.4)	5	(2.18)	0.07	0.29	0.44
Migraine	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Paresthesia	Mi	2	(4.87)	0	(0)	2	(5)	1	(2.7)	0	(0)	5	(2.18)	0.15	0.60	0.06
Loss of muscle strength	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.30	0.29	
Guillain-Barré syndrome	S	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Drowsiness	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Vertigo	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Endocrine disorders	Total	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Hyperprolactinemia	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Hypothyroidism	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	im az	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Gastrointestinal disorders	Total	13	(31.7)	7	(17.5)	16	(40)	7	(18.91)	15	(21.12)	58	(25.32)	0.13	0.04	0.21
	Mi	11	(26.82)	7	(17.5)	15	(37.5)	7	(18.91)	12	(16.9)	52	(22.7)	0.31	0.07	0.21
	Мо	3	(7.31)	0	(0)	1	(2.5)	0	(0)	4	(5.63)	8	(3.49)	0.08	0.33	0.72
	S	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Dental caries	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Colitis	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
Colitis	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Diarrhea	Mi	2	(4.87)	3	(7.5)	3	(7.5)	1	(2.7)	2	(2.81)	11	(4.8)	0.62	0.34	0.57
Diarrhea	Мо	2	(4.87)	0	(0)	0	(0)	0	(0)	1	(1.4)	3	(1.31)	0.15		0.27
Dyspepsia	Mi	0	(0)	1	(2.5)	1	(2.5)	1	(2.7)	1	(1.4)	4	(1.74)	0.30	0.95	0.44
Dyspepsia	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Abdominal distension	Mi	0	(0)	0	(0)	0	(0)	2	(5.4)	0	(0)	2	(0.87)		0.13	
Abdominal pain	Mi	0	(0)	1	(2.5)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.30	0.33	
Lower abdominal pain	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Periodontal disease	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Gastroesophageal reflux disease	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Gastroesophageal reflux disease	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Gastritis	Mi	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
Glossitis	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Inguinal hernia	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Food poisoning	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Nausea	Mi	1	(2.43)	1	(2.5)	1	(2.5)	0	(0)	1	(1.4)	4	(1.74)	0.98	0.33	0.69
Odynophagia	Mi	4	(9.75)	1	(2.5)	7	(17.5)	2	(5.4)	3	(4.22)	17	(7.42)	0.17	0.09	0.24
Odynophagia	Мо	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
Acute pancreatitis	S	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Rectal polyp	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Irritable bowel syndrome	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	1	(1.4)	2	(0.87)		0.29	0.44

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	im az	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Vomiting	Mi	1	(2.43)	1	(2.5)	0	(0)	0	(0)	0	(0)	2	(0.87)	0.98		0.18
Aphthous ulcer	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
General disorders and administration site conditions	Total	25	(60.97)	8	(20)	14	(35)	8	(21.62)	18	(25.35)	73	(31.87)	0.0002	0.19	0.0002
	Mi	24	(58.53)	8	(20)	14	(35)	7	(18.91)	17	(23.94)	70	(30.56)	0.0004	0.11	0.0003
	Мо	2	(4.87)	0	(0)	0	(0)	1	(2.7)	1	(1.4)	4	(1.74)	0.15	0.29	0.27
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Asthenia	Mi	1	(2.43)	2	(5)	3	(7.5)	4	(10.81)	3	(4.22)	13	(5.67)	0.54	0.61	0.62
Axillary Pain	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Injection Site Pain	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Chest Pain	Mi	16	(39.02)	5	(12.5)	0	(0)	0	(0)	10	(14.08)	31	(13.53)	0.006		0.002
Flu-like Illness	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Chill	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Fatigue	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
General Discomfort	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Chest Discomfort	Mi	2	(4.87)	1	(2.5)	3	(7.5)	0	(0)	1	(1.4)	7	(3.05)	0.57	0.08	0.27
Fever	Mi	5	(12.19)	0	(0)	4	(10)	2	(5.4)	1	(1.4)	12	(5.24)	0.02	0.45	0.01
Dry Skin	Mi	3	(7.31)	0	(0)	4	(10)	1	(2.7)	4	(5.63)	12	(5.24)	0.08	0.19	0.72
Asthenia	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Axillary Pain	Mi	5	(12.19)	1	(2.5)	2	(5)	2	(5.4)	6	(8.45)	16	(6.98)	0.09	0.93	0.52
Injection Site Pain	Мо	1	(2.43)	0	(0)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.32	0.29	0.18
Chest Pain	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Musculoskeletal and connective tissue disorders	Total	11	(26.82)	8	(20)	8	(20)	6	(16.21)	14	(19.71)	47	(20.52)	0.45	0.66	0.38
	Mi	9	(21.95)	8	(20)	6	(15)	6	(16.21)	14	(19.71)	43	(18.77)	0.82	0.88	0.77
	Мо	2	(4.87)	0	(0)	2	(5)	0	(0)	1	(1.4)	5	(2.18)	0.15	0.16	0.27
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Joint pain	Mi	2	(4.87)	0	(0)	1	(2.5)	0	(0)	4	(5.63)	7	(3.05)	0.15	0.33	0.86
Bruising	Mi	1	(2.43)	1	(2.5)	0	(0)	1	(2.7)	2	(2.81)	5	(2.18)	0.98	0.29	0.90

SOC	РТ	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
	Costochondritis	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Back pain	Mi	1	(2.43)	1	(2.5)	2	(5)	0	(0)	2	(2.81)	6	(2.62)	0.98	0.16	0.90
	Back pain	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Pain in a limb	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Ligament sprain	Mi	1	(2.43)	1	(2.5)	0	(0)	0	(0)	0	(0)	2	(0.87)	0.98		0.18
	Ligament sprain	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Muscle spasms	Mi	0	(0)	1	(2.5)	1	(2.5)	1	(2.7)	0	(0)	3	(1.31)	0.30	0.95	
	Muscle spasms	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Myalgia	Mi	5	(12.19)	3	(7.5)	3	(7.5)	3	(8.1)	6	(8.45)	20	(8.73)	0.47	0.92	0.52
	Myalgia	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Osteopenia	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Tendonitis	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	1	(1.4)	3	(1.31)	0.30	0.29	0.44
Eye di	isorders	Total	2	(4.87)	2	(5)	3	(7.5)	2	(5.4)	1	(1.4)	10	(4.36)	0.97	0.70	0.27
		Mi	2	(4.87)	2	(5)	2	(5)	2	(5.4)	1	(1.4)	9	(3.93)	0.97	0.93	0.27
		Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Allergic Conjunctivitis	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Conjunctivitis	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Eye pain	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
	Photopsia	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Sty on the eyelid	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Conjunctival hemorrhage	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Iris hemorrhage	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Eye discomfort	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
	Abnormal sensation in the eye	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.30	0.29	
Psych	iatric Disorders	Total	1	(2.43)	1	(2.5)	4	(10)	0	(0)	4	(5.63)	10	(4.36)	0.98	0.04	0.43
		Mi	1	(2.43)	1	(2.5)	3	(7.5)	0	(0)	3	(4.22)	8	(3.49)	0.98	0.08	0.62
		Мо	0	(0)	0	(0)	2	(5)	0	(0)	2	(2.81)	4	(1.74)		0.16	0.27

SO	С РТ	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Agitation	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Attention Impairment	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.30		0.44
	Anxiety	Mi	1	(2.43)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	3	(1.31)	0.32	0.33	0.69
	Depression	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Stress	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Insomnia	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Panic Reaction	Мо	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Mixed Anxiety and Depressive Disorder	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Sleep Disorder	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Ren	al and Urinary Disorders	Total	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
		Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
		Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
		S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Renal Colic	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Dysuria	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Res	piratory, thoracic, and liastinal disorders	Total	12	(29.26)	10	(25)	15	(37.5)	9	(24.32)	11	(15.49)	57	(24.89)	0.66	0.21	0.08
		Mi	12	(29.26)	10	(25)	15	(37.5)	9	(24.32)	10	(14.08)	56	(24.45)	0.66	0.21	0.05
		Мо	1	(2.43)	0	(0)	2	(5)	0	(0)	0	(0)	3	(1.31)	0.32	0.16	0.18
		S	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
	Dyspnea	S	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Pharyngolaryngeal pain	Mi	0	(0)	0	(0)	0	(0)	2	(5.4)	0	(0)	2	(0.87)		0.13	
	Pharyngolaryngeal pain	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
	Pharyngeal erythema	Mi	1	(2.43)	5	(12.5)	2	(5)	1	(2.7)	0	(0)	9	(3.93)	0.08	0.60	0.18
	Epistaxis	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Pharyngotonsillitis	Mi	0	(0)	0	(0)	0	(0)	3	(8.1)	2	(2.81)	5	(2.18)		0.06	0.27
	Pharyngotonsillitis	Mi	1	(2.43)	0	(0)	3	(7.5)	1	(2.7)	0	(0)	5	(2.18)	0.32	0.34	0.18

SO	рт	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
	Hypertrophy of nasal	Mi	2	(4.87)	0	(0)	3	(7.5)	2	(5.4)	1	(1.4)	8	(3.49)	0.15	0.70	0.27
	Throat irritation	Мо	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
	Nasal discomfort	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Nasopharyngitis	Mi	0	(0)	0	(0)	0	(0)	2	(5.4)	0	(0)	2	(0.87)		0.13	
	Allergic rhinitis	Mi	0	(0)	0	(0)	2	(5)	0	(0)	0	(0)	2	(0.87)		0.16	
	Rhinorrhea	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	Nasal dryness	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Cough	Mi	6	(14.63)	4	(10)	6	(15)	5	(13.51)	3	(4.22)	24	(10.48)	0.52	0.85	0.05
	Cough	Mi	0	(0)	0	(0)	2	(5)	0	(0)	0	(0)	2	(0.87)		0.16	
	Laryngeal disorder	Mi	4	(9.75)	1	(2.5)	2	(5)	3	(8.1)	5	(7.04)	15	(6.55)	0.17	0.58	0.61
	Dyspnea	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Pharyngolaryngeal pain	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Vas	cular Disorders	Total	3	(7.31)	0	(0)	4	(10)	1	(2.7)	3	(4.22)	11	(4.8)	0.08	0.19	0.48
		Mi	3	(7.31)	0	(0)	4	(10)	1	(2.7)	3	(4.22)	11	(4.8)	0.08	0.19	0.48
		Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Hypertensive crisis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Peripheral Vascular Disease	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Hematoma	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
	Hemorrhoids	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Hypertension	Mi	1	(2.43)	0	(0)	3	(7.5)	1	(2.7)	0	(0)	5	(2.18)	0.32	0.34	0.18
	Hypotension	Mi	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18

SOC: System Organ Class; PT: Preferred Term; AE: adverse event; SEV: severity; Mi: mild; Mo: moderate; S: severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: intramuscular; IN: intranasal; PL: placebo. p-value calculated from the comparison of proportions (Z-test).

# Table 2S. Proportion of affected subjects by local adverse events of special interest at 7 days post-immunization.

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Subjects		41		40		40		37		71		229				
Locally AE	Total	17	(41.46)	6	(15)	7	(17.5)	2	(5.4)	12	(16.9)	44	(19.21)	0.008	0.09	0.004
	Mi	16	(39.02)	6	(15)	7	(17.5)	2	(5.4)	12	(16.9)	43	(18.77)	0.01	0.09	0.009
	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Skin and Subcutaneous Tissue Disorders	Total	0	(0)	1	(2.5)	1	(2.5)	0	(0)	2	(2.81)	4	(1.74)	0.30	0.33	0.27
	Mi	0	(0)	1	(2.5)	1	(2.5)	0	(0)	2	(2.81)	4	(1.74)	0.30	0.33	0.27
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Erythema	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Pruritus	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(2.81)	3	(1.31)	0.30		0.27
General disorders and administration site conditions	Total	17	(41.46)	5	(12.5)	0	(0)	0	(0)	10	(14.08)	32	(13.97)	0.003		0.001
	Mi	16	(39.02)	5	(12.5)	0	(0)	0	(0)	10	(14.08)	31	(13.53)	0.006		0.002
	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Injection Site Pain	Mi	16	(39.02)	5	(12.5)	0	(0)	0	(0)	10	(14.08)	31	(13.53)	0.006		0.002
Injection Site Pain	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Respiratory, thoracic, and mediastinal disorders	Total	0	(0)	0	(0)	7	(17.5)	2	(5.4)	0	(0)	9	(3.93)		0.09	
	Mi	0	(0)	0	(0)	7	(17.5)	2	(5.4)	0	(0)	9	(3.93)		0.09	
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Epistaxis	Mi	0	(0)	0	(0)	3	(7.5)	1	(2.7)	0	(0)	4	(1.74)		0.34	
Pharyngeal erythema	Mi	0	(0)	0	(0)	0	(0)	2	(5.4)	0	(0)	2	(0.87)		0.13	
Nasal discomfort	Mi	0	(0)	0	(0)	2	(5)	0	(0)	0	(0)	2	(0.87)		0.16	
Nasal dryness	Mi	0	(0)	0	(0)	2	(5)	0	(0)	0	(0)	2	(0.87)		0.16	

SOC: System Organ Class; PT: Preferred Term; AE: Adverse Event; SEV: Severity; Mi: Mild; Mo: Moderate; S: Severe, AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: Intramuscular; IN: Intranasal; PL: Placebo. P-value calculated from comparison of proportions (Z-test).

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Subjects		41		40		40		37		71		229				
Systemic AE	Total	24	(58.53)	20	(50)	23	(57.5)	15	(40.54)	19	(26.76)	101	(44.1)	0.44	0.13	0.0009
	Mi	23	(56.09)	20	(50)	23	(57.5)	14	(37.83)	19	(26.76)	99	(43.23)	0.58	0.08	0.002
	Мо	3	(7.31)	1	(2.5)	2	(5)	2	(5.4)	2	(2.81)	10	(4.36)	0.31	0.93	0.26
	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Traumatic injuries, poisonings, and complications of therapeutic procedures	Total	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Injection-Related Reaction	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Cardiac Disorders	Total	0	(0)	0	(0)	1	(2.5)	1	(2.7)	0	(0)	2	(0.87)		0.95	
	Mi	0	(0)	0	(0)	1	(2.5)	1	(2.7)	0	(0)	2	(0.87)		0.95	
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Palpitations	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Tachycardia	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Skin and Subcutaneous Tissue Disorders	Total	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	1	(1.4)	2	(0.87)		0.33	0.44
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Dermatitis	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Hyperhidrosis	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Reproductive and breast disorders	Total	0	(0)	1	(2.5)	0	(0)	1	(2.7)	2	(2.81)	4	(1.74)	0.30	0.29	0.27
	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(2.81)	3	(1.31)	0.30		0.27

Table 3S. Proportion of affected subjects by systemic adverse events of special interest at 7 days postimmunization.

soc	PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
		Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	1	(1.4)	2	(0.87)		0.29	0.44
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Dysmenorrhea	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Menstrual disorders	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.30		0.44
	Menstrual disorders	Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	1	(1.4)	2	(0.87)		0.29	0.44
Diso	rders of the ear and labyrinth	Total	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
		Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
		Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Vertigo	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Diso	rders of the nervous system	Total	14	(34.14)	10	(25)	12	(30)	9	(24.32)	9	(12.67)	54	(23.58)	0.36	0.57	0.006
		Mi	13	(31.7)	10	(25)	12	(30)	9	(24.32)	8	(11.26)	52	(22.7)	0.50	0.57	0.007
		Мо	1	(2.43)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	3	(1.31)	0.98		0.69
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Headache	Mi	13	(31.7)	9	(22.5)	12	(30)	9	(24.32)	7	(9.85)	50	(21.83)	0.35	0.57	0.003
	Headache	Мо	1	(2.43)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	3	(1.31)	0.98		0.69
	Dizziness	Mi	0	(0)	2	(5)	0	(0)	1	(2.7)	0	(0)	3	(1.31)	0.14	0.29	
	Paresthesia	Mi	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
	Loss of muscle strength	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.30	0.29	
	Drowsiness	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Gas	rointestinal disorders	Total	6	(14.63)	3	(7.5)	7	(17.5)	1	(2.7)	2	(2.81)	19	(8.29)	0.30	0.03	0.01
		Mi	6	(14.63)	3	(7.5)	7	(17.5)	1	(2.7)	2	(2.81)	19	(8.29)	0.30	0.03	0.01
		Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
		S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	Diarrhea	Mi	1	(2.43)	0	(0)	2	(5)	1	(2.7)	0	(0)	4	(1.74)	0.32	0.60	0.18
	Lower abdominal pain	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
	Abdominal pain	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
	Nausea	Mi	1	(2.43)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	3	(1.31)	0.98		0.69

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	im az	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
Odynophagia	Mi	4	(9.75)	0	(0)	5	(12.5)	0	(0)	0	(0)	9	(3.93)	0.04	0.02	0.007
Vomiting	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
General disorders and administration site conditions	Total	11	(26.82)	4	(10)	12	(30)	5	(13.51)	10	(14.08)	42	(18.34)	0.05	0.08	0.09
	Mi	11	(26.82)	4	(10)	12	(30)	4	(10.81)	10	(14.08)	41	(17.9)	0.05	0.03	0.09
	Мо	1	(2.43)	0	(0)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.32	0.29	0.18
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Asthenia	Mi	1	(2.43)	2	(5)	3	(7.5)	2	(5.4)	3	(4.22)	11	(4.8)	0.54	0.70	0.62
Asthenia	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Axillary Pain	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Chills	Mi	2	(4.87)	1	(2.5)	3	(7.5)	0	(0)	1	(1.4)	7	(3.05)	0.57	0.08	0.27
Fatigue	Mi	3	(7.31)	0	(0)	4	(10)	2	(5.4)	0	(0)	9	(3.93)	0.08	0.45	0.02
General discomfort	Mi	3	(7.31)	0	(0)	4	(10)	1	(2.7)	4	(5.63)	12	(5.24)	0.08	0.19	0.72
Chest tightness	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Fever	Mi	4	(9.75)	1	(2.5)	0	(0)	1	(2.7)	6	(8.45)	12	(5.24)	0.17	0.29	0.81
Fever	Мо	0	(0)	0	(0)	0	(0)	1	(2.7)	0	(0)	1	(0.43)		0.29	
Musculoskeletal and connective tissue disorders	Total	4	(9.75)	4	(10)	4	(10)	3	(8.1)	2	(2.81)	17	(7.42)	0.97	0.77	0.11
	Mi	3	(7.31)	4	(10)	3	(7.5)	3	(8.1)	2	(2.81)	15	(6.55)	0.66	0.92	0.26
	Мо	1	(2.43)	0	(0)	1	(2.5)	0	(0)	0	(0)	2	(0.87)	0.32	0.33	0.18
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Arthralgia	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	2	(2.81)	3	(1.31)	0.32		0.90
Back pain	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Back pain	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
Myalgia	Mi	2	(4.87)	3	(7.5)	2	(5)	2	(5.4)	2	(2.81)	11	(4.8)	0.62	0.93	0.57
Myalgia	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Muscle spasms	Mi	0	(0)	1	(2.5)	0	(0)	1	(2.7)	0	(0)	2	(0.87)	0.30	0.29	
Respiratory, thoracic, and mediastinal disorders	Total	6	(14.63)	9	(22.5)	4	(10)	5	(13.51)	0	(0)	24	(10.48)	0.36	0.63	0.0009
	Mi	6	(14.63)	9	(22.5)	4	(10)	5	(13.51)	0	(0)	24	(10.48)	0.36	0.63	0.0009

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p- value	IN AVX- PL p- value	AVX- AZ p- value
	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Pharyngolaryngeal pain	Mi	1	(2.43)	5	(12.5)	0	(0)	1	(2.7)	0	(0)	7	(3.05)	0.08	0.29	0.18
Pharyngolaryngeal pain	S	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Throat irritation	Mi	0	(0)	0	(0)	0	(0)	2	(5.4)	0	(0)	2	(0.87)		0.13	
Rhinorrhea	Mi	5	(12.19)	3	(7.5)	4	(10)	4	(10.81)	0	(0)	16	(6.98)	0.47	0.90	0.002
Cough	Mi	2	(4.87)	1	(2.5)	0	(0)	2	(5.4)	0	(0)	5	(2.18)	0.57	0.13	0.06
Cough	Мо	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC: System Organ Class; PT: Preferred Term; AE: Adverse Event; SEV: Severity; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: Intramuscular; IN: Intranasal; PL: Placebo. p-value calculated from comparison of proportions (Z-test).

Table	4S.	Proportion	of	subjects	affected	by	adverse	events	associated	with	vaccination	at	7	days	post-
immur	nizat	ion.		-		-								-	-

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p	IN AVX- PL p	AVX- AZ p
Subjects		41		40		40		37		71		229				
Any AE	Total	6	(14.63)	4	(10)	3	(7.5)	1	(2.7)	7	(9.85)	21	(9.17)	0.52	0.34	0.44
	Mi	6	(14.63)	4	(10)	3	(7.5)	1	(2.7)	7	(9.85)	21	(9.17)	0.52	0.34	0.44
	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Skin and Subcutaneous Tissue Disorders	Total	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Pruritus	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.30		
Disorders of the nervous system	Total	4	(9.75)	1	(2.5)	1	(2.5)	1	(2.7)	4	(5.63)	11	(4.8)	0.17	0.95	0.41
	Mi	3	(7.31)	1	(2.5)	1	(2.5)	1	(2.7)	3	(4.22)	9	(3.93)	0.31	0.95	0.48
	Мо	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Headache	Mi	3	(7.31)	1	(2.5)	1	(2.5)	1	(2.7)	2	(2.81)	8	(3.49)	0.31	0.95	0.26
Headache	М	1	(2.43)	0	(0)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.32		0.69
Drowsiness	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Gastrointestinal disorders	Total	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Odynophagia	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
General disorders and administration site conditions	Total	5	(12.19)	3	(7.5)	0	(0)	0	(0)	7	(9.85)	15	(6.55)	0.47		0.70
	Mi	5	(12.19)	3	(7.5)	0	(0)	0	(0)	7	(9.85)	15	(6.55)	0.47		0.70
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			

SOC PT	SEV	IM AVX	%	IM PL	%	IN AVX	%	IN PL	%	IM AZ	%	Total	%	IM AVX- PL p	IN AVX- PL p	AVX- AZ p
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Asthenia	Mi	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(1.4)	2	(0.87)	0.30		0.44
Injection Site Pain	Mi	5	(12.19)	3	(7.5)	0	(0)	0	(0)	6	(8.45)	14	(6.11)	0.47		0.52
Chill	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
General Discomfort	Mi	0	(0)	0	(0)	0	(0)	0	(0)	1	(1.4)	1	(0.43)			0.44
Pirexia	Mi	0	(0)	0	(0)	0	(0)	0	(0)	2	(2.81)	2	(0.87)			0.27
Musculoskeletal and connective tissue disorders	Total	1	(2.43)	0	(0)	2	(5)	0	(0)	0	(0)	3	(1.31)	0.32	0.16	0.18
	Mi	1	(2.43)	0	(0)	2	(5)	0	(0)	0	(0)	3	(1.31)	0.32	0.16	0.18
	М	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Arthralgia	Mi	1	(2.43)	0	(0)	0	(0)	0	(0)	0	(0)	1	(0.43)	0.32		0.18
Myalgia	Mi	0	(0)	0	(0)	2	(5)	0	(0)	0	(0)	2	(0.87)		0.16	
Respiratory, thoracic, and mediastinal disorders	Total	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	
	Мо	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
	S	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)			
Rhinorrhea	Mi	0	(0)	0	(0)	1	(2.5)	0	(0)	0	(0)	1	(0.43)		0.33	

SOC: System Organ Class (clasificación de eventos por órganos y sistemas); PT: Preferred Term (término preferido); EA: Adverse Event (evento adverso); SEV: severity (severidad); Mi: mild (leve); Mo: moderate (moderado); S: severe (severo), AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: intranuscular; IN: intranasal; PL: placebo. P value calculated from comparison of proportions (Z-test).

# Table 5S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 via intramuscular route.

			IM AVX/COVID	-12		
	Baseline	Day 14	Day 42	Day 90	Day 180	Day 365
Volunteers	41	38	38	39	39	36
Antibody titer	s IgG against	spike protein				
GM	227.06	2171.4	1489	1399.7	1013.4	1514.2
CI	166 - 310.5	1609.2 - 2930	1083.8 - 2045.9	977.4 - 2004.4	651.4 - 1576.4	1054.2 - 2174.8
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001
Wuhan-1 neut	ralizing titers					
GM	37.2	308.7	509.7	372.5	382.8	513.9
CI	28.8 - 48.2	205.5 - 463.6	347.4 - 747.8	226.2 - 613.6	217.2 - 674.7	332 - 795.6
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001
Delta neutraliz	zing titers					
GM	20.2	68.3	87.4	118.2	150.1	211.5
CI	17.8 - 23.1	45.9 - 101.6	55.3 - 138.2	71.2 - 196.1	91.5 - 246.1	132.3 - 337.9
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001
Alpha neutral	izing titers					
GM	39.5	292.68	742.6	452.2	437.3	372.7
CI	30 - 52	209.1 - 409.7	443.3 - 1244	281.3 - 726.8	255.7 - 747.7	234.5 - 592.5
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001
Beta neutraliz	ing titers					
GM	24.8	62.4	89.1	103.4	110.4	244.3
CI	20.8 - 29.7	42.5 - 91.7	55 - 144.2	62.7 - 170.5	67.1 - 181.9	151 - 395.4
p-Value		0.002	<0.001	<0.001	<0.001	<0.001
BA.2 neutraliz	ing titers*					
GM	23.6	88.2	ND	ND	ND	ND
CI	20.3 - 27.5	55.6 - 139.7				
p-Value		<0.001				
BA.5 neutraliz	ing titers*					
GM	23	143	ND	ND	ND	ND
CI	19.7 - 26.9	94.5 - 216.3				
p-Value		<0.001				

\*Sample size n=39, AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM tested with Wilcoxon signed-rank test (paired), variable on logarithmic scale.

# Table 6S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 intramuscularly who did not experience COVID-19 during the study.

		AVX/CO	VID-12 IM		
	Day 14	Day 42	Day 90	Day 180	Day 365
Sujetos	34	28	25	15	12
Antibody titers lo	gG against spike prot	tein			
GM	2056.2	1226.6	1022	388.6	1133.9

CI	1496.4 - 2825.6	844.3 - 1782.1	651.5 - 1603	197.8 - 763.4	463 - 2776.8
Wuhan-1 neutra	lizing titers				
GM	289	404.3	286.3	142.4	466.9
CI	185.9 - 449.1	258.1 - 633.4	158.2 - 518	63.9 - 317.6	164.7 - 1323.4
Delta neutralizin	g titers				
GM	60.6	57.8	70.4	57.6	201.8
CI	39.7 - 92.3	35.9 - 93.1	40.1 - 123.7	34.3 - 96.8	70.3 - 579.1
Alpha neutralizi	ng titers				
GM	286.4	603.1	346.9	192.1	338.7
CI	197.2- 416.1	328.2 - 1107.8	188.9 - 636.9	79.1- 466.4	108.7 - 1055.4
Beta neutralizing	g titers				
GM	55.3	70.5	58.9	44.7	226.9
CI	37.3 - 82.1	40.4 - 122.8	33.3 - 104	25 - 80	71.3 - 721.3
BA.2 neutralizin	g titers				
GM	76.6	ND	ND	ND	ND
CI	47.3 - 124				
BA.5 neutralizin	g titers				
GM	130.1	ND	ND	ND	ND
CI	83.8 - 202.2				

AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM using Wilcoxon signed-rank test (paired), variable on a logarithmic scale.

Table 7S. Antibody titers over the study duration in subjects vaccinated with AVX/COVID-12 via the intranasal route.

AVX/COVID-12 IN							
	Baseline	Day 14	Day 42	Day 90	Day 180	Day 365	
Volunteers	40	39	38	38	37	36	
Antibody titers IgG against spike protein							
GM	253.7	1340.9	1181.6	917.8	1820.5	1763.7	
CI	186.6 - 344.9	1034.5 - 1738	871.5 - 1601.9	619.2 - 1360.3	1203.2 - 2754.3	1158.3 - 2685.5	
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001	
Wuhan-1 neutralizing titers							
GM	28.7	219.5	362.9	305.2	759.6	721.5	
CI	22.8 - 36	156.3 - 308.1	255.8 - 514.8	182.5 - 510.3	433.1 - 1332.3	438.9 - 1185.9	
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001	
Delta neutralizing titers							
GM	20.7	40.9	57.4	77	281.5	293.4	
CI	19.7 - 21.7	29.5 - 56.8	39.7 - 83.1	46.3 - 128.2	165.5 - 478.9	177.6 - 484.8	
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001	
Alpha neutralizing titers							
GM	36.9	274.9	481.2	357.1	782	577.3	
CI	27.5 - 49.5	201.1-375.8	299.7 - 772.6	205.7 - 619.9	453.4 - 1348.8	354.8 - 939.3	
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001	
Beta neutralizing titers							
GM	20.8	49.3	89.1	67.8	206.1	355.9	
CI	19.6 - 22.2	36.1 - 67.5	55 - 144.4	40.7 - 112.9	122.5 - 346.5	216.6 - 584.9	
p-Value		<0.001	<0.001	<0.001	<0.001	<0.001	
BA.2 neutralizing titers*							
GM	23.9	58	ND	ND	ND	ND	
CI	20.2 - 28.4	38.7 - 87					
p-Value		<0.001					

#### BA.5 neutralizing titers\*

GM	26	111.83	ND	ND	ND	ND
CI	21.3 - 31.7	76.4 - 163.5				
p-Value		<0.001				

\*Sample size n=39, AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM tested with Wilcoxon signed-rank test (paired), variable on logarithmic scale.

# Table 8S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 intranasally who did not experience COVID-19 during the study.

AVX/COVID-12 IN							
	Day 14	Dav 42	Day 90	Day 180	Day 365		
Subjects	37	32	29	21	15		
Antibody titers IgG against spike protein							
GM	1267.2	993.9	704.1	1417.1	1451.2		
CI	977.7 - 1642.4	736.7 - 1340.9	470 - 1054.9	750.2 - 2676.9	597.3 - 3525.7		
Wuhan-1 neutralizing titers							
GM	205.1	302.1	214.9	525.8	509.8		
CI	145.7 - 288.6	216.4 - 421.8	124.8 - 370	221.3 - 1249	196.1 - 1325.1		
Delta neutralizing titers							
GM	37	48.4	48.9	179.8	242.5		
CI	27.1 - 50.5	33.5 - 69.9	30.2 - 79.2	81.9 - 394.7	90.2 - 652		
Alpha neutralizing titers							
GM	262.5	363.3	248.8	571.1	359.3		
CI	190.2 - 362.2	229.9 - 574.2	131.8 - 469.3	234.4 -1391.6	139 - 928.9		
Beta neutralizing titers							
GM	46.3	64.2	41.4	131.3	248.2		
CI	33.7 - 63.6	40.9 - 101	25.9 - 66.2	60.6 - 284.2	99.3 - 620.2		
BA.2 neutralizing titers*							
GM	51.2	ND	ND	ND	ND		
CI	34.8 - 75.3						
BA.5 neutralizing titers*							
GM	107.6	ND	ND	ND	ND		
CI	72.2 - 160.2						

\*Sample size n=36, AVX: AVX/COVID-12; IN: intranasal; ND: not determined; GM: geometric mean; CI: confidence interval. GM comparison test with Wilcoxon signed-rank test, variable on a logarithmic scale.